{"content":"<li class=\"n-box-item date-title\" data-end=\"1483505999\" data-start=\"1483419600\" data-txt=\"Sunday, December 22, 2019\">Tuesday, January  3, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3233275\" data-ts=\"1483490055\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LIVE\" target=\"_blank\">LIVE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233275-live-ventures-to-expand-ir-activities-outreach\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Live Ventures to expand IR activities, outreach</a></h4><ul>   <li>On a bit of a run over the past month (<font color='green'>up 53%</font>), Live Ventures (<a href='https://seekingalpha.com/symbol/LIVE' title='Live Ventures'>LIVE</a> <font color='red'>-2.5%</font>) is expanding its outreach to investors with <a href=\"https://seekingalpha.com/pr/16703109-live-ventures-announces-launch-expanded-investor-relations-activities-2017\" target=\"_blank\">new investor relations activities</a> beginning in Q1.</li>    <li>The company will launch quarterly conference calls and \"may conduct investor days where members of the financial community can pose questions directly to management in an open forum.\" It also plans to set up local market roadshows and boost its social media presence.</li>    <li>\"We intend to dedicate significant time and resources to communicating with our shareholder base, as well as potential investors, including institutions, who may take positions in our stock,&rdquo; says CEO Jon Isaac.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3233275\" data-linked=\"Live Ventures to expand IR activities, outreach\" data-tweet=\"$LIVE - Live Ventures to expand IR activities, outreach https://seekingalpha.com/news/3233275-live-ventures-to-expand-ir-activities-outreach?source=tweet\" data-url=\"https://seekingalpha.com/news/3233275-live-ventures-to-expand-ir-activities-outreach\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:34 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233274\" data-ts=\"1483489858\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLVS\" target=\"_blank\">CLVS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233274-clovis-oncology-prices-upsized-205m-share-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Clovis Oncology prices upsized $205M share offering</a></h4><ul>   <li>Clovis Oncology (<a href='https://seekingalpha.com/symbol/CLVS' title='Clovis Oncology'>CLVS</a> <font color='red'>-3.3%</font>) has <a href=\"https://seekingalpha.com/pr/16703972-clovis-oncology-announces-upsizing-pricing-public-offering-common-stock\" target=\"_blank\">priced a now-upsized public offering</a> of $205M in common stock.</li>    <li>The company <a href=\"https://seekingalpha.com/news/3233033-clovis-readies-equity-offering\" target=\"_blank\">planned a $175M offering</a>, and has raised terms now to 5M shares at $41/share. Underwriters have a typical 30-day option to buy up to an additional 750,000 shares on the same terms.</li>    <li>The offering's expected to close Jan. 9. J.P. Morgan and BofA Merrill Lynch are joint book-runners, with Stifel and SunTrust Robinson Humphrey co-managers.</li>    <li>After hours, shares are <font color='red'>down another 1.4%</font> to $42.37.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3233274\" data-linked=\"Clovis Oncology prices upsized $205M share offering\" data-tweet=\"$CLVS - Clovis Oncology prices upsized $205M share offering https://seekingalpha.com/news/3233274-clovis-oncology-prices-upsized-205m-share-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3233274-clovis-oncology-prices-upsized-205m-share-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:30 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233271\" data-ts=\"1483487093\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CTL\" target=\"_blank\">CTL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233271-jpmorgan-upgrades-centurylink-to-buy-on-dividend-level-3-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">JPMorgan upgrades CenturyLink to Buy on dividend, Level 3 deal</a></h4><ul>   <li>CenturyLink (NYSE:<a href='https://seekingalpha.com/symbol/CTL' title='CenturyLink, Inc.'>CTL</a>) <font color='green'>rose 6.6%</font> to its highest point in six weeks after a JPMorgan upgrade to Overweight.</li>    <li>The firm likes the dividend (now at more than 9% forward yield) and the $34B plan to buy Level 3 Communications (<a href='https://seekingalpha.com/symbol/LVLT' title='Level 3 Communications, Inc.'>LVLT</a> <font color='green'>+4.6%</font>).</li>    <li>\"We believe the Level 3 deal is a <a href=\"http://blogs.barrons.com/incomeinvesting/2017/01/03/research-time-to-buy-centurylink-stock-but-not-the-bonds/\" target=\"_blank\">significant positive for CTL</a> as it brings a higher enterprise mix (~75% of pro forma revenue), increased scale, revenue and EBITDA stability, and tax protection to help CTL pay its dividend,\" writes analyst Philip Cusick. \"Despite the benefits, CTL&rsquo;s dividend yield is at record levels vs the 10 year Treasury as well as T/VZ dividend yields. We are replacing LVLT [Overweight] with CTL on the J.P. Morgan US Equity Analyst Focus List as an income pick.\"</li>    <li>Cusick has a price target of $28, implying 10.5% upside from today's close.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3233271\" data-linked=\"JPMorgan upgrades CenturyLink to Buy on dividend, Level 3 deal\" data-tweet=\"$CTL $CTL $LVLT - JPMorgan upgrades CenturyLink to Buy on dividend, Level 3 deal https://seekingalpha.com/news/3233271-jpmorgan-upgrades-centurylink-to-buy-on-dividend-level-3-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3233271-jpmorgan-upgrades-centurylink-to-buy-on-dividend-level-3-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:44 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233262\" data-ts=\"1483485026\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IDXX\" target=\"_blank\">IDXX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233262-idexx-labs-to-join-s-and-p-500-chemours-bumps-up-to-s-and-p-midcap-400\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">IDEXX Labs to join S&amp;P 500, Chemours bumps up to S&amp;P MidCap 400</a></h4><ul><li>IDEXX Laboratories (NASDAQ:<a href='https://seekingalpha.com/symbol/IDXX' title='IDEXX Laboratories, Inc.'>IDXX</a>) <a href=\"https://www.spice-indices.com/idpfiles/spice-assets/resources/public/documents/465757_idxx5cc4shak6.pdf?force_download=true\" target=\"_blank\">will join the S&amp;P 500</a>, effective after the close on Jan. 4, replacing St. Jude Medical (NYSE:<a href='https://seekingalpha.com/symbol/STJ' title='St. Jude Medical, Inc.'>STJ</a>), which is being acquired by Abbott Laboratories.</li><li>Chemours (NYSE:<a href='https://seekingalpha.com/symbol/CC' title='The Chemours Company'>CC</a>) will replace IDXX in the S&amp;P MidCap 400, and Shake Shack (NYSE:<a href='https://seekingalpha.com/symbol/SHAK' title='Shake Shack'>SHAK</a>) will replace Chemours in the S&amp;P SmallCap 600.</li><li>IDXX&nbsp;<font color='green'>+0.6%</font>, CC&nbsp;<font color='green'>+1.5%</font>, SHAK <font color='green'>+4.6%</font> AH.</li></ul><div class=\"tiny-share-widget\" data-id=\"3233262\" data-linked=\"IDEXX Labs to join S&amp;P 500, Chemours bumps up to S&amp;P MidCap 400\" data-tweet=\"$IDXX $IDXX $STJ - IDEXX Labs to join S&amp;P 500, Chemours bumps up to S&amp;P MidCap 400 https://seekingalpha.com/news/3233262-idexx-labs-to-join-s-and-p-500-chemours-bumps-up-to-s-and-p-midcap-400?source=tweet\" data-url=\"https://seekingalpha.com/news/3233262-idexx-labs-to-join-s-and-p-500-chemours-bumps-up-to-s-and-p-midcap-400\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:10 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233257\" data-ts=\"1483483872\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SXE\" target=\"_blank\">SXE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233257-southcross-energy-gets-amendment-to-revolving-credit-agreement\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Southcross Energy gets amendment to revolving credit agreement</a></h4><ul>     <li>Southcross Energy Partners (NYSE:<a href='https://seekingalpha.com/symbol/SXE' title='Southcross Energy Partners'>SXE</a>) <font color='green'>+2.9%</font>&nbsp;AH after announcing it secured an amendment to its revolving credit agreement that provides for a <a href=\"https://seekingalpha.com/pr/16703881-southcross-energy-partners-l-p-announces-amendment-revolving-credit-facility-new-equity\" target=\"_blank\">full two-year suspension of leverage covenants</a> in the credit agreement through 2018.</li>     <li>SXE says the amendment effects a reduction of the total revolver commitment to $145M from $200M, with further reductions to $115M by year-end 2018, and establishes certain additional covenant requirements.</li>     <li>SXE also receives a $17M investment from the parent of its general partner, to be used to pay down revolver borrowings and for general partnership purposes; SXE issued ~11.5M common units in  exchange for the investment.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3233257\" data-linked=\"Southcross Energy gets amendment to revolving credit agreement\" data-tweet=\"$SXE $SXE-OLD - Southcross Energy gets amendment to revolving credit agreement https://seekingalpha.com/news/3233257-southcross-energy-gets-amendment-to-revolving-credit-agreement?source=tweet\" data-url=\"https://seekingalpha.com/news/3233257-southcross-energy-gets-amendment-to-revolving-credit-agreement\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:51 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233253\" data-ts=\"1483482970\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233253-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers, as of 5.25 p.m.:</b> EBIO <font color='green'>+2.5%</font>. <a href='https://seekingalpha.com/symbol/LW' title='Lamb Weston Holdings, Inc.'>LW</a> <font color='green'>+1.5%</font>. <a href='https://seekingalpha.com/symbol/KOPN' title='Kopin Corporation'>KOPN</a> <font color='green'>+1.5%</font>. <a href='https://seekingalpha.com/symbol/CCU' title='Compania Cervecerias Unidas S.A.'>CCU</a> <font color='green'>+1.4%</font>. <a href='https://seekingalpha.com/symbol/BWXT' title='BWX Technologies, Inc.'>BWXT</a> <font color='green'>+1.3%</font>.</li><li><b>Top losers, as of 5.25p.m.:</b> <a href='https://seekingalpha.com/symbol/WETF' title='WisdomTree Investments, Inc.'>WETF</a> <font color='red'>-6.0%</font>. <a href='https://seekingalpha.com/symbol/PDLI' title='PDL BioPharma, Inc.'>PDLI</a> <font color='red'>-5.2%</font>. <a href='https://seekingalpha.com/symbol/CGI' title='Celadon Group, Inc.'>CGI</a> <font color='red'>-4.4%</font>. <a href='https://seekingalpha.com/symbol/WLB' title='Westmoreland Coal Co'>WLB</a> <font color='red'>-4.1%</font>. <a href='https://seekingalpha.com/symbol/MTGE' title='MTGE Investment Corp.'>MTGE</a> <font color='red'>-3.3%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3233253\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$SESN $LW $KOPN - After Hours Gainers / Losers https://seekingalpha.com/news/3233253-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3233253-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233252\" data-ts=\"1483482728\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BLDP\" target=\"_blank\">BLDP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233252-ballard-says-first-to-power-fuel-cell-electric-buses-for-10m-km-revenue-service\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ballard says first to power fuel cell electric buses for 10M km revenue service</a></h4><ul>     <li>Ballard Power (NASDAQ:<a href='https://seekingalpha.com/symbol/BLDP' title='Ballard Power Systems, Inc.'>BLDP</a>)&nbsp;<font color='green'>+2.9%</font>&nbsp;AH after announcing it is the <a href=\"https://seekingalpha.com/pr/16703902-ballard-first-power-fuel-cell-electric-buses-10-plus-million-kilometers-revenue-service\" target=\"_blank\"> first fuel cell company</a> to power electric buses for 10M-plus cumulative kilometers of revenue service.</li>     <li>BLDP says it is seeing increased market demand for its FCveloCity fuel cell engines of various sizes for use in a number of different vehicle types.</li>     <li>\"We are moving beyond technical validation into commercial scaling at a time where market demand is at a breakthrough inflection point,\" says BLDP&nbsp;CEO and President Randy MacEwen.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3233252\" data-linked=\"Ballard says first to power fuel cell electric buses for 10M km revenue service\" data-tweet=\"$BLDP - Ballard says first to power fuel cell electric buses for 10M km revenue service https://seekingalpha.com/news/3233252-ballard-says-first-to-power-fuel-cell-electric-buses-for-10m-km-revenue-service?source=tweet\" data-url=\"https://seekingalpha.com/news/3233252-ballard-says-first-to-power-fuel-cell-electric-buses-for-10m-km-revenue-service\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:32 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233246\" data-ts=\"1483481338\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CMCSA\" target=\"_blank\">CMCSA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233246-considering-m-prospects-citigroup-upgrades-verizon-to-buy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Considering M&amp;A prospects, Citigroup upgrades Verizon to Buy</a></h4><ul>   <li>Verizon (<a href='https://seekingalpha.com/symbol/VZ' title='Verizon Communications'>VZ</a> <font color='green'>+2.3%</font>) has a number of <a href=\"http://www.investors.com/news/technology/verizon-upgraded-ma-likely-to-improve-strategic-position/\" target=\"_blank\">M&amp;A prospects ahead</a> that might prove as catalysts to improve its position, Citigroup writes in an upgrade to Buy.</li>    <li>The market may be getting cautious on the telecom's upside potential, but a prospective lighter regulatory touch from the incoming government could set up a number of scenarios in which Verizon could benefit, says analyst Michael Rollins.</li>    <li>Aside from its plans to acquire the core of Yahoo (<a href=\"https://seekingalpha.com/symbol/YHOO\" target=\"_blank\">YHOO</a> <font color='green'>+0.6%</font>) early this year, Verizon could target Dish Network (<a href='https://seekingalpha.com/symbol/DISH' title='DISH Network Corporation'>DISH</a> <font color='green'>+3%</font>), Rollins says. But strategic ties could be built between Verizon and Comcast (NASDAQ:<a href='https://seekingalpha.com/symbol/CMCSA' title='Comcast Corporation'>CMCSA</a>) as well as with Charter Communications (<a href='https://seekingalpha.com/symbol/CHTR' title='Charter Communications, Inc.'>CHTR</a> <font color='red'>-0.8%</font>), Reinhardt Krause notes.</li>    <li>\"Verizon is pursuing growth in three categories (Internet of Things, digital media, and 5G) that are somewhat small today, but can eventually contribute to revenue growth and value,\" Rollins writes. \"We don't believe Verizon is getting credit for the investments to date and see a bull case emerging for 5G.\"</li>    <li>Rollins has a price target of $60, implying 10% upside.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3233246\" data-linked=\"Considering M&amp;A prospects, Citigroup upgrades Verizon to Buy\" data-tweet=\"$CMCSA $CMCSA $VZ - Considering M&amp;A prospects, Citigroup upgrades Verizon to Buy https://seekingalpha.com/news/3233246-considering-m-prospects-citigroup-upgrades-verizon-to-buy?source=tweet\" data-url=\"https://seekingalpha.com/news/3233246-considering-m-prospects-citigroup-upgrades-verizon-to-buy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:08 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233244\" data-ts=\"1483481101\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AGRX\" target=\"_blank\">AGRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233244-agiles-positive-late-stage-trial-data-for-contraceptive-patch-twirla-aint-positive-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Agile&#39;s &quot;positive&quot; late-stage trial data for contraceptive patch Twirla ain&#39;t so positive; shares plummet 74% after hours</a></h4><ul><li>Thinly traded micro cap Agile Therapeutics' (NASDAQ:<a href='https://seekingalpha.com/symbol/AGRX' title='Agile Therapeutics, Inc.'>AGRX</a>) craters&nbsp;<font color='red'>74%</font>&nbsp;after hours on robust volume in response to the <a href=\"https://seekingalpha.com/pr/16703778-agile-therapeutics-announces-positive-top-line-phase-3-results\" target=\"_blank\">release of data</a> from the Phase 3 SECURE study assessing combined hormonal contraceptive patch Twirla in 2,032 American women aged 18 - 35. The company conducted the study at the request of the FDA, which rejected its initial marketing application in 2013.</li><li>Agile refers to the data as \"positive\" but it is anything but. For starters, Twirla's efficacy in preventing pregnancy, measured by a ratio called the Pearl Index &#40;PI&#41;, was higher than expected in several patient groups, specifically overweight and obese women. Analysts were apparently expecting values less than four, but the results were 5.36 - 6.42. The PI values were on the mark for normal weight (3.03) and non-obese (3.94) women. In the overall intent-to-treat population, the PI range (95% confidence interval) was 4.80 - 6.06, far above expectations.</li><li>Also troubling was the 51.4% discontinuation rate. The most frequent adverse events were headache (4.3%), nausea (4.1%), breast tenderness/discomfort (2.0%), mood swings/changes/depression (2.7%) and heavy/irregular vaginal bleeding (1.8%). Serious adverse events occurred in 1.7% of subjects. Of reported patches worn, 17% experience patch site irritation and 35% experienced itching (the company worded it as \"83% experienced no patch site irritation\" and \"65% had no itching\").</li><li>Despite the poor showing, Agile says it intends to resubmit the NDA in H1.</li><li>Management will host a conference call today at 5:00 pm ET to discuss the data.</li></ul><div class=\"tiny-share-widget\" data-id=\"3233244\" data-linked=\"Agile&#39;s &quot;positive&quot; late-stage trial data for contraceptive patch Twirla ain&#39;t so positive; shares plummet 74% after hours\" data-tweet=\"$AGRX - Agile&#39;s &quot;positive&quot; late-stage trial data for contraceptive patch Twirla ain&#39;t so positive; shares plummet 74% after hours https://seekingalpha.com/news/3233244-agiles-positive-late-stage-trial-data-for-contraceptive-patch-twirla-aint-positive-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3233244-agiles-positive-late-stage-trial-data-for-contraceptive-patch-twirla-aint-positive-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:05 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233228\" data-ts=\"1483478382\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CBAY\" target=\"_blank\">CBAY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233228-cymabay-out-licenses-arhalofenate-in-u-s-in-deal-valued-up-to-205m-shares-up-1-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CymaBay out-licenses arhalofenate in U.S. in deal valued up to $205M; shares up 1% after hours</a></h4><ul><li>Thinly traded nano cap CymaBay Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/CBAY' title='CymaBay Therapeutics'>CBAY</a>) is up&nbsp;<font color='green'>1%</font>&nbsp;after hours, albeit on only 45 shares, in response to its <a href=\"https://seekingalpha.com/pr/16703719-cymabay-announces-exclusive-licensing-agreement-kowa-pharmaceuticals-america-inc-development\" target=\"_blank\">announcement </a>that it has inked an exclusive license agreement with Kowa Pharmaceuticals America for the development and commercialization of gout candidate arhalofenate in the U.S.</li><li>Under the terms of the deal, CymaBay will receive up to $15M upfront, up to $190M in milestones and tiered double-digit royalties on net sales. Kowa will be responsible for all development and commercialization costs. CymaBay retains all ex-U.S. rights.</li><li><a href=\"http://www.webmd.com/arthritis/tc/gout-topic-overview\" target=\"_blank\">Gout&nbsp;</a>is a type of arthritis caused by too much uric acid in the blood.&nbsp;<a href=\"http://www.cymabay.com/pipeline_arhalofenate.html\" target=\"_blank\">Arhalofenate&nbsp;</a>lowers serum uric acid by blocking the reabsorption of uric acid in the proximal tubes of the kidney by inhibiting the renal uric acid transporter, URAT1.</li></ul><div class=\"tiny-share-widget\" data-id=\"3233228\" data-linked=\"CymaBay out-licenses arhalofenate in U.S. in deal valued up to $205M; shares up 1% after hours\" data-tweet=\"$CBAY - CymaBay out-licenses arhalofenate in U.S. in deal valued up to $205M; shares up 1% after hours https://seekingalpha.com/news/3233228-cymabay-out-licenses-arhalofenate-in-u-s-in-deal-valued-up-to-205m-shares-up-1-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3233228-cymabay-out-licenses-arhalofenate-in-u-s-in-deal-valued-up-to-205m-shares-up-1-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:19 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233223\" data-ts=\"1483478135\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DS\" target=\"_blank\">DS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233223-drive-shack-up-9-following-name-change\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Drive Shack up more than 9% following name change</a></h4><ul><li>Newcastle Investment (NCT) today began trading as Drive Shack (NYSE:<a href='https://seekingalpha.com/symbol/DS' title='Drive Shack Inc'>DS</a>) as the company makes clear its transformation to golf course/leisure activity operation.</li><li>The company is also no longer a REIT, but a C-Corp.</li><li>Investors bought the news, sending DS&nbsp;<font color='green'>higher by 9.6%</font>.</li><li>Manager Fortress Investment (NYSE:<a href='https://seekingalpha.com/symbol/FIG' title='Fortress Investment Group LLC'>FIG</a>) shot&nbsp;<font color='green'>up 6.4%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3233223\" data-linked=\"Drive Shack up more than 9% following name change\" data-tweet=\"$DS $DS $FIG - Drive Shack up more than 9% following name change https://seekingalpha.com/news/3233223-drive-shack-up-9-following-name-change?source=tweet\" data-url=\"https://seekingalpha.com/news/3233223-drive-shack-up-9-following-name-change\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:15 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233219\" data-ts=\"1483477709\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AGRX\" target=\"_blank\">AGRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233219-agile-and-cymabay-trading-halted-pending-news\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Agile and CymaBay trading halted pending news</a></h4><ul><li>Nasdaq suspends after hours trading in Agile Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/AGRX' title='Agile Therapeutics, Inc.'>AGRX</a>) and CymaBay Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/CBAY' title='CymaBay Therapeutics'>CBAY</a>) pending news.</li></ul><div class=\"tiny-share-widget\" data-id=\"3233219\" data-linked=\"Agile and CymaBay trading halted pending news\" data-tweet=\"$AGRX $AGRX $CBAY - Agile and CymaBay trading halted pending news https://seekingalpha.com/news/3233219-agile-and-cymabay-trading-halted-pending-news?source=tweet\" data-url=\"https://seekingalpha.com/news/3233219-agile-and-cymabay-trading-halted-pending-news\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:08 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233214\" data-ts=\"1483477209\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IDXG\" target=\"_blank\">IDXG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233214-interpace-inks-4_2m-direct-capital-raise\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Interpace inks $4.2M direct capital raise</a></h4><ul><li>Interpace Diagnostics Group (<a href='https://seekingalpha.com/symbol/IDXG' title='Interpace Diagnostics Group, Inc.'>IDXG</a> <font color='green'>+94.3%</font>) enters into a securities purchase agreement with institutional investors for the <a href=\"https://www.sec.gov/Archives/edgar/data/1054102/000143774917000033/ex99-1.htm\" target=\"_blank\">direct sale</a> of 375K common shares at $6.75 and 255K pre-funded warrants to purchase common shares at $6.74. Closing date is January 6.</li><li>Net proceeds of ~$3.7M will fund working capital, the repayment of indebtedness and general corporate purposes.</li></ul><div class=\"tiny-share-widget\" data-id=\"3233214\" data-linked=\"Interpace inks $4.2M direct capital raise\" data-tweet=\"$IDXG - Interpace inks $4.2M direct capital raise https://seekingalpha.com/news/3233214-interpace-inks-4_2m-direct-capital-raise?source=tweet\" data-url=\"https://seekingalpha.com/news/3233214-interpace-inks-4_2m-direct-capital-raise\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233213\" data-ts=\"1483476893\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SALT\" target=\"_blank\">SALT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233213-scorpio-bulkersplus-15-deutsche-bank-upgrades-to-buy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Scorpio Bulkers +15% as Deutsche Bank upgrades to Buy</a></h4><ul>     <li>Scorpio Bulkers (<a href='https://seekingalpha.com/symbol/SALT' title='Scorpio Bulkers Inc'>SALT</a> <font color='green'>+15.3%</font>) surges after Deutsche Bank <a href=\"http://www.streetinsider.com/Analyst+Comments/Deutsche+Bank+Upgrades+Scorpio+Bulkers+%28SALT%29+to+Buy/12383249.html\" target=\"_blank\">upgrades shares to Buy</a> from Hold with a $7.25 price target, with the firm saying it has become incrementally more positive on the outlook for the dry bulk shipping industry.</li><li>Deutsche Bank says its bullish stance is based more on a belief that the market bottomed in 2016 and should behave more rationally in 2017 and beyond, rather than because of China&rsquo;s long-term demand for raw materials.</li><li>The firm also views balance sheets as largely benign, following highly dilutive equity offerings in 2016 and exponential increases in share counts.</li>     </ul><div class=\"tiny-share-widget\" data-id=\"3233213\" data-linked=\"Scorpio Bulkers +15% as Deutsche Bank upgrades to Buy\" data-tweet=\"$SALT - Scorpio Bulkers +15% as Deutsche Bank upgrades to Buy https://seekingalpha.com/news/3233213-scorpio-bulkersplus-15-deutsche-bank-upgrades-to-buy?source=tweet\" data-url=\"https://seekingalpha.com/news/3233213-scorpio-bulkersplus-15-deutsche-bank-upgrades-to-buy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:54 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233212\" data-ts=\"1483476754\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DIS\" target=\"_blank\">DIS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233212-rogue-one-pushes-disney-past-3b-year-studio-milestone\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">&#39;Rogue One&#39; pushes Disney past $3B-year studio milestone</a></h4><ul>   <li><i>Rogue One: A Star Wars Story</i> led domestic films at the box office for the holiday weekend and gave Walt Disney (<a href='https://seekingalpha.com/symbol/DIS' title='The Walt Disney Company'>DIS</a> <font color='green'>+1.7%</font>) its final push toward a unique milestone: the $3B mark.</li>    <li>With $49.5M in the three days, the <i>Star Wars</i> story held its lead over second-week films <i>Sing</i> (<a href='https://seekingalpha.com/symbol/CMCSA' title='Comcast Corporation'>CMCSA</a> <font color='red'>-0.1%</font>), with $42.8M, and <i>Passengers</i> (<a href='https://seekingalpha.com/symbol/SNE' title='Sony Corporation'>SNE</a> <font color='green'>+1%</font>), with $16.2M. (For the four-day holiday weekend, <i>Rogue One</i> drew $64.3M; <i>Sing</i> $56.4M; and <i>Passengers</i> $20.7M. Disney's <i>Moana</i> took fourth for good measure with $14.3M.)</li>    <li><i>Rogue One's</i> solid weekend pushed it to $789.7M worldwide.</li>    <li>With 2016 numbers in, Disney became the first studio ever to mark a $3B year at the domestic box office. As with other milestones for the studio this year, its cause was led by its \"Big Three\" (the industry's three biggest grossers overall): <i>Finding Dory</i> ($486.3M domestic); <i>Rogue One</i> ($439.7M and counting); and <i>Captain America: Civil War</i> ($408.1M).</li> </ul><div class=\"tiny-share-widget\" data-id=\"3233212\" data-linked=\"&#39;Rogue One&#39; pushes Disney past $3B-year studio milestone\" data-tweet=\"$DIS $DIS $CMCSA - &#39;Rogue One&#39; pushes Disney past $3B-year studio milestone https://seekingalpha.com/news/3233212-rogue-one-pushes-disney-past-3b-year-studio-milestone?source=tweet\" data-url=\"https://seekingalpha.com/news/3233212-rogue-one-pushes-disney-past-3b-year-studio-milestone\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:52 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>19&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233206\" data-ts=\"1483475871\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LCI\" target=\"_blank\">LCI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233206-fda-oks-lannetts-generic-kaletra-shares-ahead-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA OKs Lannett&#39;s generic Kaletra; shares ahead 2%</a></h4><ul><li>The FDA <a href=\"http://www.prnewswire.com/news-releases/lannett-announces-approval-for-lopinavir-and-ritonavir-oral-solution-usp-80-mg20-mg-per-ml-300384790.html\" target=\"_blank\">approves </a>Lannett Company's (<a href='https://seekingalpha.com/symbol/LCI' title='Lannett Company, Inc'>LCI</a> <font color='green'>+2.3%</font>) Abbreviated New Drug Application &#40;ANDA&#41; for Lopinavir and Ritonavir Oral Solution USP, 80 mg/20 mg/mL for the treatment of HIV-1 infection, the therapeutic equivalent to AbbVie's (<a href='https://seekingalpha.com/symbol/ABBV' title='AbbVie Inc.'>ABBV</a> <font color='red'>-0.7%</font>) <a href=\"http://www.kaletra.com/\" target=\"_blank\">Kaletra </a>Oral Solution.</li></ul><div class=\"tiny-share-widget\" data-id=\"3233206\" data-linked=\"FDA OKs Lannett&#39;s generic Kaletra; shares ahead 2%\" data-tweet=\"$LCI $LCI $ABBV - FDA OKs Lannett&#39;s generic Kaletra; shares ahead 2% https://seekingalpha.com/news/3233206-fda-oks-lannetts-generic-kaletra-shares-ahead-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3233206-fda-oks-lannetts-generic-kaletra-shares-ahead-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233203\" data-ts=\"1483474658\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CUDA\" target=\"_blank\">CUDA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233203-barracuda-networksplus-3_6-jmp-securities-takes-off-sell-rating\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Barracuda Networks +3.6%; JMP Securities takes off Sell rating</a></h4><ul>   <li>Barracuda Networks (NYSE:<a href='https://seekingalpha.com/symbol/CUDA' title='Barracuda Networks, Inc'>CUDA</a>) is <font color='green'>up 3.6%</font> today, recovering some holiday-week doldrums after JMP Securities switched up its take and moved the stock from Market Underperform to Market Perform.</li>    <li>A heavy pullback compared to the rest of the market has <a href=\"http://www.benzinga.com/analyst-ratings/analyst-color/17/01/8857393/for-barracuda-networks-jmp-securities-changes-its-tune\" target=\"_blank\">reduced downside risk</a>, Erik Suppiger says, and the company closed out the November quarter nicely.</li>    <li>The stock's still at a premium to peers, but it's justified due to the \"attractive catalyst\" of emerging cloud solutions. &ldquo;We believe morale has improved and that the company&rsquo;s increased focus on high-growth areas is beginning to bear fruit.\"</li> </ul><div class=\"tiny-share-widget\" data-id=\"3233203\" data-linked=\"Barracuda Networks +3.6%; JMP Securities takes off Sell rating\" data-tweet=\"$CUDA - Barracuda Networks +3.6%; JMP Securities takes off Sell rating https://seekingalpha.com/news/3233203-barracuda-networksplus-3_6-jmp-securities-takes-off-sell-rating?source=tweet\" data-url=\"https://seekingalpha.com/news/3233203-barracuda-networksplus-3_6-jmp-securities-takes-off-sell-rating\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:17 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233200\" data-ts=\"1483473690\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233200-technology-top-5-gainers-losers-of-3-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top 5 Gainers / Losers as of 3:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/NIHD' title='NII Holdings, Inc.'>NIHD</a> <font color='green'>+37%</font>. <a href='https://seekingalpha.com/symbol/TISA' title='Top Image Systems, Ltd.'>TISA</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/KOPN' title='Kopin Corporation'>KOPN</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/CEL' title='Cellcom Israel, Ltd.'>CEL</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/CRNT' title='Ceragon Networks Ltd.'>CRNT</a> <font color='green'>+12%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/SITO' title='SITO Mobile, Ltd.'>SITO</a> <font color='red'>-32%</font>. DRAM <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/EIGI' title='Endurance International Group Holdings, Inc.'>EIGI</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/CPSH' title='CPS Technologies Corp.'>CPSH</a> <font color='red'>-14%</font>. MSDI <font color='red'>-3%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3233200\" data-linked=\"Technology - Top 5 Gainers / Losers as of 3:00 pm\" data-tweet=\"$NIHD $TISA $KOPN - Technology - Top 5 Gainers / Losers as of 3:00 pm https://seekingalpha.com/news/3233200-technology-top-5-gainers-losers-of-3-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3233200-technology-top-5-gainers-losers-of-3-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233198\" data-ts=\"1483473555\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CEI\" target=\"_blank\">CEI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233198-lucas-energy-enters-permian-basin-leasehold-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lucas Energy enters Permian Basin with leasehold deal</a></h4><ul>     <li>Lucas Energy (LEI <font color='green'>+3.2%</font>) is higher following news that it was set to <a href=\"https://seekingalpha.com/pr/16702828-lucas-energy-enters-permian-basin-purchase-3630-net-mineral-acres\" target=\"_blank\">gain a toehold in the Permian Basin</a> after via a $1.7M lease acquisition and participation contract with an unnamed company.</li>     <li>LEI will acquire a 90% working interest for more than 16.3K gross acres of petroleum properties plus another 3,640 net acres of mineral properties for a $1.43M cash payment.</li>     <li>Lucas CEO Anthony Schnur calls the purchase a&nbsp;&ldquo;potentially transformational transaction.&rdquo;</li> </ul><div class=\"tiny-share-widget\" data-id=\"3233198\" data-linked=\"Lucas Energy enters Permian Basin with leasehold deal\" data-tweet=\"$CEI - Lucas Energy enters Permian Basin with leasehold deal https://seekingalpha.com/news/3233198-lucas-energy-enters-permian-basin-leasehold-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3233198-lucas-energy-enters-permian-basin-leasehold-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:59 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233197\" data-ts=\"1483473475\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GNTX\" target=\"_blank\">GNTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233197-gentex-rallies-after-tipping-ces-reveals\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gentex rallies after tipping CES reveals</a></h4><ul> <li>Gentex (<a href='https://seekingalpha.com/symbol/GNTX' title='Gentex Corporation'>GNTX</a> <font color='green'>+2.7%</font>) trades higher after announcing that it will <a href=\"https://seekingalpha.com/pr/16702996-gentex-launch-new-rear-vision-technologies-automotive-biometrics-vehicle-connectivity\" target=\"_blank\">unveil</a> new technologies at CES 2017.</li> <li>The company says a three-camera rear vision system and a biometrics authenticating process will be debuted at the tech show. The newest version of HomeLink will also be showcased.</li><li>#CES17</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3233197\" data-linked=\"Gentex rallies after tipping CES reveals\" data-tweet=\"$GNTX - Gentex rallies after tipping CES reveals https://seekingalpha.com/news/3233197-gentex-rallies-after-tipping-ces-reveals?source=tweet\" data-url=\"https://seekingalpha.com/news/3233197-gentex-rallies-after-tipping-ces-reveals\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:57 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233195\" data-ts=\"1483472539\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/QEP\" target=\"_blank\">QEP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233195-qep-resources-jumps-on-fbr-upgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">QEP Resources jumps on FBR upgrade</a></h4><ul><li>QEP&nbsp;Resources (<a href='https://seekingalpha.com/symbol/QEP' title='QEP Resources, Inc.'>QEP</a> <font color='green'>+3.2%</font>) is <a href=\"http://www.streetinsider.com/Analyst+Comments/FBR+Capital+Upgrades+QEP+Resources+%28QEP%29+to+Outperform/12383189.html\" target=\"_blank\">upgraded</a> to Outperform from Market Perform with a $24 price target, raised from $20, at FBR, which expects the stock to  return to outperformance in the new year.</li><li>QEP lagged  its benchmark index during H2 2016, which FBR attributes to investors penalizing the  stock following a premium-priced Permian  acquisition, but the firm believes the acreage is  situated in one of the most prospective  areas of the play.</li><li>QEP also could get a lift from a new play  in the Permian, as well as its  underappreciated exposure to natural  gas, which quietly hit a two-year  high last week.</li></ul><div class=\"tiny-share-widget\" data-id=\"3233195\" data-linked=\"QEP Resources jumps on FBR upgrade\" data-tweet=\"$QEP - QEP Resources jumps on FBR upgrade https://seekingalpha.com/news/3233195-qep-resources-jumps-on-fbr-upgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3233195-qep-resources-jumps-on-fbr-upgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:42 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233191\" data-ts=\"1483471446\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GSM\" target=\"_blank\">GSM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233191-ferroglobe-executive-chairman-kestenbaum-steps-down\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ferroglobe executive chairman Kestenbaum steps down</a></h4><ul>     <li>Ferroglobe (<a href='https://seekingalpha.com/symbol/GSM' title='Ferroglobe PLC'>GSM</a> <font color='red'>-12.5%</font>) shares sink after the specialty metals producer said Executive Chairman Alan Kestenbaum had <a href=\"https://seekingalpha.com/pr/16702668-ferroglobe-executive-chairman-alan-kestenbaum-resigns-continues-senior-advisor-vice-chairman\" target=\"_blank\">resigned</a>, to be replaced by Vice Chair Javier Lopez Madrid.</li>     <li>Kestenbaum had served as Executive Chairman since GSM's inception in 2004, and was CEO from its inception to May 2008 and again from August 2015 until the closing of the business combination.</li>     <li>GSM says Kestenbaum will remain an independent board consultant on strategic and business-critical matters.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3233191\" data-linked=\"Ferroglobe executive chairman Kestenbaum steps down\" data-tweet=\"$GSM - Ferroglobe executive chairman Kestenbaum steps down https://seekingalpha.com/news/3233191-ferroglobe-executive-chairman-kestenbaum-steps-down?source=tweet\" data-url=\"https://seekingalpha.com/news/3233191-ferroglobe-executive-chairman-kestenbaum-steps-down\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:24 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233186\" data-ts=\"1483469329\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BIIB\" target=\"_blank\">BIIB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233186-drug-price-hikes-continue-ibbplus-1_4-today\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Drug price hikes continue; IBB +1.4% today</a></h4><ul><li>\"Think the Era of Drug Price Increases is Over? Think Again?\" So goes the title of a new note from Raymond James' Chris Raymond, noting a sizable number of key biotech price boosts on January 1.</li><li>Most are in-line with previous patterns, but not Biogen (<a href='https://seekingalpha.com/symbol/BIIB' title='Biogen Inc.'>BIIB</a> <font color='green'>+2.1%</font>), which was \"measurably more aggressive than norm,\" he says.</li><li>Others which pushed through increases include Acorda Therapeutics (<a href='https://seekingalpha.com/symbol/ACOR' title='Acorda Therapeutics, Inc.'>ACOR</a> <font color='green'>+1.6%</font>) and AMAG Pharma (<a href='https://seekingalpha.com/symbol/AMAG' title='AMAG Pharmaceuticals, Inc.'>AMAG</a> <font color='red'>-3.4%</font>). There's also AstraZeneca's (<a href='https://seekingalpha.com/symbol/AZN' title='AstraZeneca Group plc'>AZN</a> <font color='green'>+1%</font>) 5% price boost for Lynparza and a \"slew\" of increases at Roche (<a href='https://seekingalpha.com/symbol/RHHBY' title='Roche Holding Ltd ADR'>OTCQX:RHHBY</a> <font color='green'>+1.2%</font>), including&nbsp;Actemra up 1.5%, Herceptin up 3%, Pegasys up 5%.</li><li>Source: <a href=\"http://thefly.com/landingPageNews.php?id=2483117&amp;headline=BIIB;ACOR;AMAG;RHHBY-Biogen-Acorda-Therapeutics-AMAG-Pharmaceuticals-Roche-analyst-commentary-at-Raymond-James\" target=\"_blank\">TheFly</a></li><li><a href=\"https://twitter.com/adamfeuerstein\" target=\"_blank\">via Adam Feuerstein</a> ... Jefferies takes note of 9.9% price hikes across the board at Horizon Pharma (<a href='https://seekingalpha.com/symbol/HZNP' title='Horizon Pharma plc'>HZNP</a> <font color='green'>+2.8%</font>) and Insys Therapeutics (<a href='https://seekingalpha.com/symbol/INSY' title='Insys Therapeutics, Inc.'>INSY</a> <font color='green'>+4.7%</font>) boosted the cost of Subsys by 9.5%.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/IBB' title='iShares Nasdaq Biotechnology ETF'>IBB</a>, <a href='https://seekingalpha.com/symbol/XBI' title='SPDR Biotech ETF'>XBI</a>, <a href='https://seekingalpha.com/symbol/BBH' title='VanEck Vectors Biotech ETF'>BBH</a>, <a href='https://seekingalpha.com/symbol/FBT' title='First Trust NYSE Arca Biotechnology Index ETF'>FBT</a>, <a href='https://seekingalpha.com/symbol/HQL' title='Tekla Life Sciences Investors'>HQL</a>, <a href='https://seekingalpha.com/symbol/PBE' title='Invesco Dynamic Biotechnology & Genome Portfolio ETF'>PBE</a>, <a href='https://seekingalpha.com/symbol/LABU' title='Direxion Daily S&P Biotech Bull 3x Shares ETF'>LABU</a>, <a href='https://seekingalpha.com/symbol/BBC' title='BioShares Biotechnology Clinical Trials ETF'>BBC</a>, <a href='https://seekingalpha.com/symbol/BBP' title='BioShares Biotechnology Products ETF'>BBP</a>, <a href='https://seekingalpha.com/symbol/LABD' title='Direxion Daily S&P Biotech Bear 3x Shares ETF'>LABD</a>, <a href='https://seekingalpha.com/symbol/UBIO' title='ProShares UltraPro NASDAQ Biotechnology ETF'>UBIO</a>, <a href='https://seekingalpha.com/symbol/ZBIO' title='ProShares UltraPro Short NASDAQ Biotechnology ETF'>ZBIO</a>, <a href='https://seekingalpha.com/symbol/LABS' title='Direxion Daily S&P Biotech Bear 1X Shares ETF'>LABS</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3233186\" data-linked=\"Drug price hikes continue; IBB +1.4% today\" data-tweet=\"$BIIB $BIIB $ACOR - Drug price hikes continue; IBB +1.4% today https://seekingalpha.com/news/3233186-drug-price-hikes-continue-ibbplus-1_4-today?source=tweet\" data-url=\"https://seekingalpha.com/news/3233186-drug-price-hikes-continue-ibbplus-1_4-today\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:48 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233184\" data-ts=\"1483469193\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/P\" target=\"_blank\">P</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233184-barrington-research-downgrades-pandora-townsquare-media\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Barrington Research downgrades Pandora, Townsquare Media</a></h4><ul><li>Lowering ratings on both from Outperform to Market Perform.</li><li>Pandora (NYSE:<a href='https://seekingalpha.com/symbol/P' title='Pandora Media'>P</a>) [<a href=\"https://www.benzinga.com/analyst-ratings/analyst-color/17/01/8858646/barrington-downgrades-pandora-from-market-outperform-to-\" target=\"_blank\">valuation cited</a>] and <a href=\"https://www.benzinga.com/news/17/01/8858667/barrington-research-downgrades-townsquare-media-to-market-perform\" target=\"_blank\">Townsquare Media</a> (NYSE:<a href='https://seekingalpha.com/symbol/TSQ' title='Townsquare Media'>TSQ</a>) shares are trading for the day on respective <font color='red'>2.92%</font>&nbsp;and <font color='red'>3.94%</font> declines.</li></ul><div class=\"tiny-share-widget\" data-id=\"3233184\" data-linked=\"Barrington Research downgrades Pandora, Townsquare Media\" data-tweet=\"$P $P $TSQ - Barrington Research downgrades Pandora, Townsquare Media https://seekingalpha.com/news/3233184-barrington-research-downgrades-pandora-townsquare-media?source=tweet\" data-url=\"https://seekingalpha.com/news/3233184-barrington-research-downgrades-pandora-townsquare-media\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:46 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233177\" data-ts=\"1483466687\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XLNX\" target=\"_blank\">XLNX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233177-xilinx-downgraded-to-reduce-instinet\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Xilinx downgraded to Reduce at Instinet</a></h4><ul><li>Lowering from Neutral and setting $45 target, <a href=\"http://blogs.barrons.com/techtraderdaily/2017/01/03/xilinx-one-of-the-most-over-priced-semis-says-instinet/?mod=BOL_hp_blog_tt\" target=\"_blank\">analyst Romit Shah</a> considers Xilinx overvalued among semiconductor peers (trading at a 65%&nbsp;sector premium) and its current valuation unsustainable.</li><li>Furthermore, doesn't view M&amp;A between Xilinx and Nvidia (as speculated) probable, notes revenue growth (+10% Y/Y) only marginally superior to Intel's PSG segment (+6% Y/Y) [suggests aggressive spending underway] and projects a Xilinx tax rate increase from 14%&nbsp;in FY&nbsp;2016 to 22% in FY&nbsp;2018.</li><li>Xilinx (NASDAQ:<a href='https://seekingalpha.com/symbol/XLNX' title='Xilinx, Inc.'>XLNX</a>) <font color='red'>-2.78%</font> at $58.69.</li></ul><div class=\"tiny-share-widget\" data-id=\"3233177\" data-linked=\"Xilinx downgraded to Reduce at Instinet\" data-tweet=\"$XLNX - Xilinx downgraded to Reduce at Instinet https://seekingalpha.com/news/3233177-xilinx-downgraded-to-reduce-instinet?source=tweet\" data-url=\"https://seekingalpha.com/news/3233177-xilinx-downgraded-to-reduce-instinet\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:04 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233176\" data-ts=\"1483466641\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MTL\" target=\"_blank\">MTL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233176-barrons-14-emerging-market-stocks-you-should-owned-last-year\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Barron&#39;s: 14 emerging market stocks you should have owned last year</a></h4><ul><li>By sector, <a href=\"http://blogs.barrons.com/emergingmarketsdaily/2017/01/03/14-emerging-market-stocks-you-should-have-owned-in-2016/?mod=BOL_hp_blog_stw\" target=\"_blank\">the list </a>is dominated by commodity producers. By country the list is dominated by commodity producer Brazil, whose previously roughed-up Bovespa roared higher in 2016.</li><li>Russia's Mechel (NYSE:<a href='https://seekingalpha.com/symbol/MTL' title='Mechel OAO'>MTL</a>) gained 267%, Brazil's Co.&nbsp;Siderurgica National (NYSE:<a href='https://seekingalpha.com/symbol/SID' title='Companhia Siderurgica Nacional'>SID</a>) +242%, Brazil's Gerdau (NYSE:<a href='https://seekingalpha.com/symbol/GGB' title='Gerdau S.A.'>GGB</a>) +178%, Peru's&nbsp;Co. de Minas Buenaventura (NYSE:<a href='https://seekingalpha.com/symbol/BVN' title='Compaa de Minas Buenaventura S.A.A.'>BVN</a>) +175%, Glencore (<a href='https://seekingalpha.com/symbol/GLNCY' title='Glencore Plc ADR'>OTCPK:GLNCY</a>) +164%, Petrobas (NYSE:<a href='https://seekingalpha.com/symbol/PBR' title='Petrobras - Petroleo Brasileiro S.A.'>PBR</a>) +153%, Brazil's&nbsp;GOL Linhas Aereas (NYSE:<a href='https://seekingalpha.com/symbol/GOL' title='GOL Linhas Areas Inteligentes S.A.'>GOL</a>) +152%, Vale (NYSE:<a href='https://seekingalpha.com/symbol/VALE' title='Vale S.A.'>VALE</a>) +140%,&nbsp;Banco Santander Brasil (NYSE:<a href='https://seekingalpha.com/symbol/BSBR' title='Banco Santander &#40;Brasil&#41; S.A.'>BSBR</a>) +139%, India's&nbsp;Vedanta (NYSE:<a href='https://seekingalpha.com/symbol/VEDL' title='Vedanta Ltd'>VEDL</a>) +129%,&nbsp;Sberbank Russia (<a href='https://seekingalpha.com/symbol/SBRCY' title='Sberbank of Russia ADR'>OTCPK:SBRCY</a>) +118%, Brazil's Cosan Limited (NYSE:<a href='https://seekingalpha.com/symbol/CZZ' title='Cosan Limited'>CZZ</a>) +115%, Brazil's&nbsp;CPFL Energia (NYSE:<a href='https://seekingalpha.com/symbol/CPL' title='CPFL Energia S.A.'>CPL</a>) +115%,&nbsp;Weibo (NASDAQ:<a href='https://seekingalpha.com/symbol/WB' title='Weibo Corporation'>WB</a>) +113%.</li></ul><div class=\"tiny-share-widget\" data-id=\"3233176\" data-linked=\"Barron&#39;s: 14 emerging market stocks you should have owned last year\" data-tweet=\"$MTL $MTL $SID - Barron&#39;s: 14 emerging market stocks you should have owned last year https://seekingalpha.com/news/3233176-barrons-14-emerging-market-stocks-you-should-owned-last-year?source=tweet\" data-url=\"https://seekingalpha.com/news/3233176-barrons-14-emerging-market-stocks-you-should-owned-last-year\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:04 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>22&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233173\" data-ts=\"1483466041\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MCD\" target=\"_blank\">MCD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233173-cool-start-for-mcdonalds-in-2017\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cool start for McDonald&#39;s in 2017</a></h4><ul> <li>McDonald's (NYSE:<a href='https://seekingalpha.com/symbol/MCD' title='McDonald&#39;s Corporation'>MCD</a>) is <font color='red'>down 2.06%</font> amid some <a href=\"http://uk.reuters.com/article/us-vatican-mcdonalds-idUKKBN14N1G5\" target=\"_blank\">controversy</a> in Italy after the company opened a restaurant just outside Vatican City.</li> <li>Bloomberg notes that today's action has sent McDonald's to below its 200-day moving average - a threshold seen as significant to technical traders.</li> <li>Earlier today, a positive analyst note on Starbucks took a subtle swipe at McDonald's by predicting SBUX's market cap would rise to the largest in the sector. For that to happen, SBUX would have to bridge a gap of almost $19B in market cap.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3233173\" data-linked=\"Cool start for McDonald&#39;s in 2017\" data-tweet=\"$MCD - Cool start for McDonald&#39;s in 2017 https://seekingalpha.com/news/3233173-cool-start-for-mcdonalds-in-2017?source=tweet\" data-url=\"https://seekingalpha.com/news/3233173-cool-start-for-mcdonalds-in-2017\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:54 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233172\" data-ts=\"1483465770\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233172-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/IDXG' title='Interpace Diagnostics Group, Inc.'>IDXG</a> <font color='green'>+182%</font>. <a href='https://seekingalpha.com/symbol/BIOS' title='BioScrip, Inc.'>BIOS</a> <font color='green'>+34%</font>. <a href='https://seekingalpha.com/symbol/OREX' title='Orexigen Therapeutics, Inc.'>OREX</a> <font color='green'>+21%</font>. <a href='https://seekingalpha.com/symbol/TCON' title='Tracon Pharmaceuticals'>TCON</a> <font color='green'>+21%</font>. <a href='https://seekingalpha.com/symbol/NIHD' title='NII Holdings, Inc.'>NIHD</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/TTNP' title='Titan Pharmaceuticals, Inc.'>TTNP</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/ENG' title='ENGlobal Corporation'>ENG</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/ARTW' title='Art&#39;s-Way Manufacturing Co., Inc.'>ARTW</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/PLG' title='Platinum Group Metals Ltd'>PLG</a> <font color='green'>+15%</font>.</li><li><b>Losers:</b> ITEK <font color='red'>-72%</font>. <a href='https://seekingalpha.com/symbol/SITO' title='SITO Mobile, Ltd.'>SITO</a> <font color='red'>-32%</font>. DRAM <font color='red'>-24%</font>. <a href='https://seekingalpha.com/symbol/XRX' title='Xerox Corporation'>XRX</a>&nbsp;<font color='red'>-22%</font>. <a href='https://seekingalpha.com/symbol/EIGI' title='Endurance International Group Holdings, Inc.'>EIGI</a> <font color='red'>-17%</font>. SYMX <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/AGRX' title='Agile Therapeutics, Inc.'>AGRX</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/GSM' title='Ferroglobe PLC'>GSM</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/LEJU' title='Leju Holdings Limited'>LEJU</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/GVP' title='GSE Systems, Inc'>GVP</a> <font color='red'>-11%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3233172\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$IDXG $BIOS $OREX - Midday Gainers / Losers https://seekingalpha.com/news/3233172-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3233172-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:49 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233168\" data-ts=\"1483464824\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KSU\" target=\"_blank\">KSU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233168-kansas-city-southern-falls-after-ford-cancels-mexico-plant\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kansas City Southern falls after Ford cancels Mexico plant</a></h4><ul><li>Kansas City Southern (<a href='https://seekingalpha.com/symbol/KSU' title='Kansas City Southern'>KSU</a> <font color='red'>-3.4%</font>) breaks lower after Ford decides not to build a $1.6B plant in Mexico.</li><li>This <a href=\"http://www.acwr.com/economic-development/rail-maps/kansas-city-southern\" target=\"_blank\">interactive map</a> of KSU's transportation routes gives an indication of how important trade with Mexico is to the company.</li></ul><div class=\"tiny-share-widget\" data-id=\"3233168\" data-linked=\"Kansas City Southern falls after Ford cancels Mexico plant\" data-tweet=\"$KSU - Kansas City Southern falls after Ford cancels Mexico plant https://seekingalpha.com/news/3233168-kansas-city-southern-falls-after-ford-cancels-mexico-plant?source=tweet\" data-url=\"https://seekingalpha.com/news/3233168-kansas-city-southern-falls-after-ford-cancels-mexico-plant\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:33 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>25&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233162\" data-ts=\"1483463495\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BIOS\" target=\"_blank\">BIOS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233162-lake-street-likes-bioscrip-shares-ahead-25\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lake Street likes BioScrip; shares ahead 25%</a></h4><ul><li>In a report, Lake Street Capital says micro cap <a href=\"http://www.bioscrip.com/\" target=\"_blank\">BioScrip's </a>(<a href='https://seekingalpha.com/symbol/BIOS' title='BioScrip, Inc.'>BIOS</a> <font color='green'>+24.5%</font>) fair value is $4.50, implying a tidy 246% upside. Positive catalysts include a new experienced and talented CEO (Daniel Greenleaf), a solid platform and \"strong playbook.\"</li><li>Analyst Brooks O'Neil also cites the attractiveness of the company's niche, <a href=\"http://www.bioscrip.com/infusion-services\" target=\"_blank\">infusion services</a>, a $10B market in the U.S. growing at 5 - 7% per annum.</li></ul><div class=\"tiny-share-widget\" data-id=\"3233162\" data-linked=\"Lake Street likes BioScrip; shares ahead 25%\" data-tweet=\"$BIOS - Lake Street likes BioScrip; shares ahead 25% https://seekingalpha.com/news/3233162-lake-street-likes-bioscrip-shares-ahead-25?source=tweet\" data-url=\"https://seekingalpha.com/news/3233162-lake-street-likes-bioscrip-shares-ahead-25\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:11 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233163\" data-ts=\"1483463272\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XRX\" target=\"_blank\">XRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233163-xerox-rallies-after-conduent-separation-analyst-upgrades\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Xerox rallies after Conduent separation, analyst upgrades</a></h4><ul> <li>JPMorgan sees significant margin expansion for Xerox (NYSE:<a href='https://seekingalpha.com/symbol/XRX' title='Xerox Corporation'>XRX</a>) as it begins regular trading today following the spinoff of Conduent. Analyst Paul Coster <a href=\"https://www.marketbeat.com/stocks/NYSE/XRX/\" target=\"_blank\">lines up</a> an Overweight rating and $10.50 price target.</li> <li>Credit Suisse is also bullish, upgrading Xerox to Outperform from Neutral and assigning a price target of $8.</li> <li>Shares of Xerox are <font color='green'>up 16%</font> to $6.66. Earlier Seeking Alpha posts on the Conduent separation and premarket movers didn't factor in the distribution into the share price movement.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3233102-xerox-sets-conduent-free\" target=\"_blank\">Xerox sets Conduent free</a> (Jan. 3)</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3233163\" data-linked=\"Xerox rallies after Conduent separation, analyst upgrades\" data-tweet=\"$XRX $CNDT - Xerox rallies after Conduent separation, analyst upgrades https://seekingalpha.com/news/3233163-xerox-rallies-after-conduent-separation-analyst-upgrades?source=tweet\" data-url=\"https://seekingalpha.com/news/3233163-xerox-rallies-after-conduent-separation-analyst-upgrades\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:07 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233159\" data-ts=\"1483462759\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PIH\" target=\"_blank\">PIH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233159-1347-property-insuranceminus-8-after-updating-on-strategic-review\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">1347 Property Insurance -8% after updating on strategic review</a></h4><ul><li><a href=\"https://seekingalpha.com/pr/16702502-1347-property-insurance-holdings-inc-provides-update-strategic-review-process-announces\" target=\"_blank\">After the close Friday</a>, the company announced \"significant progress\" on its strategic and capital allocation review. Details, however, will have to wait until the company reports its Q4 and full-year results in March.</li><li>Board member L. Christopher Saenger has resigned, and been replaced by D. Kyle Cerminara.</li><li><a href='https://seekingalpha.com/symbol/PIH' title='1347 Property Insurance Holdings, Inc.'>PIH</a>&nbsp;<font color='red'>-8.3%</font></li></ul><div class=\"tiny-share-widget\" data-id=\"3233159\" data-linked=\"1347 Property Insurance -8% after updating on strategic review\" data-tweet=\"$PIH - 1347 Property Insurance -8% after updating on strategic review https://seekingalpha.com/news/3233159-1347-property-insuranceminus-8-after-updating-on-strategic-review?source=tweet\" data-url=\"https://seekingalpha.com/news/3233159-1347-property-insuranceminus-8-after-updating-on-strategic-review\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:59 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233158\" data-ts=\"1483462707\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233158-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/WATT' title='Energous Corp.'>WATT</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/PME' title='Pingtan Marine Enterprise Ltd.'>PME</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> XNY <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3233158\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$WATT $PME $DXF - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3233158-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3233158-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:58 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233157\" data-ts=\"1483462663\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CHK\" target=\"_blank\">CHK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233157-nat-gas-tumbles-8_5-arctic-blast-now-seen-shorter-expected\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nat gas tumbles 8.5% as Arctic blast now seen shorter than expected</a></h4><ul>     <li><a href=\"http://www.wsj.com/articles/natural-gas-falls-on-warmer-weather-forecast-1483461285\" target=\"_blank\">Natural gas futures plunge 8.5%</a> as weather forecasts predict temperatures will swing higher in the coming weeks, the latest sharp swing in recent weeks as prices react to shifts in the short term weather outlook.</li>     <li>The Arctic blast is now expected to be briefer than many anticipated, with milder temperatures taking hold in mid-January, which analysts say could bring an end to a string of big withdrawals of natural gas from storage.</li><li>Among individual stocks: <a href='https://seekingalpha.com/symbol/CHK' title='Chesapeake Energy Corporation'>CHK</a> <font color='red'>-2%</font>, <a href='https://seekingalpha.com/symbol/SWN' title='Southwestern Energy Co.'>SWN</a> <font color='red'>-9.3%</font>, <a href='https://seekingalpha.com/symbol/COG' title='Cabot Oil & Gas Corporation'>COG</a> <font color='red'>-5.7%</font>, <a href='https://seekingalpha.com/symbol/RRC' title='Range Resources Corporation'>RRC</a> <font color='red'>-5.6%</font>, <a href='https://seekingalpha.com/symbol/RICE' title='Rice Energy Inc'>RICE</a> <font color='red'>-6.6%</font>, <a href='https://seekingalpha.com/symbol/EQT' title='EQT Corporation'>EQT</a> <font color='red'>-3.5%</font>, <a href='https://seekingalpha.com/symbol/AR' title='Antero Resources Corporation'>AR</a> <font color='red'>-0.8%</font>.</li>     <li>ETFs: <a href='https://seekingalpha.com/symbol/UNG' title='The United States Natural Gas ETF, LP'>UNG</a>, <a href='https://seekingalpha.com/symbol/UGAZ' title='VelocityShares 3x Long Natural Gas ETN'>UGAZ</a>, <a href='https://seekingalpha.com/symbol/DGAZ' title='VelocityShares 3x Inverse Natural Gas ETN'>DGAZ</a>, <a href='https://seekingalpha.com/symbol/BOIL' title='ProShares Ultra Bloomberg Natural Gas ETF'>BOIL</a>, <a href='https://seekingalpha.com/symbol/GAZ-OLD' title='iPath DJ-UBS Natural Gas Total Return Sub-Index ETN'>GAZ-OLD</a>, <a href='https://seekingalpha.com/symbol/KOLD' title='ProShares UltraShort Bloomberg Natural Gas ETF'>KOLD</a>, <a href='https://seekingalpha.com/symbol/UNL' title='The United States 12 Month Natural Gas ETF, LP'>UNL</a>, <a href='https://seekingalpha.com/symbol/DCNG' title='iPath Pure Beta Seasonal Natural Gas ETN'>DCNG</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3233157\" data-linked=\"Nat gas tumbles 8.5% as Arctic blast now seen shorter than expected\" data-tweet=\"$CHK $CHK $SWN - Nat gas tumbles 8.5% as Arctic blast now seen shorter than expected https://seekingalpha.com/news/3233157-nat-gas-tumbles-8_5-arctic-blast-now-seen-shorter-expected?source=tweet\" data-url=\"https://seekingalpha.com/news/3233157-nat-gas-tumbles-8_5-arctic-blast-now-seen-shorter-expected\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:57 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>46&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233155\" data-ts=\"1483462125\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DIS\" target=\"_blank\">DIS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233155-disneyplus-2-evercore-boosts-to-top-pick\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Disney +2% as Evercore boosts to a top pick</a></h4><ul>   <li>Walt Disney (NYSE:<a href='https://seekingalpha.com/symbol/DIS' title='The Walt Disney Company'>DIS</a>) is <font color='green'>up 2%</font> to mark a new 52-week high after Evercore ISI moved to upgrade shares to one of its top picks.</li>    <li>The firm has a Buy rating and price target of $120, implying 13% upside. Overall, analysts tend to split between Hold and Buy and consensus price target is around $109 vs today's $106.26.</li>    <li>Evercore's price target is one of the most bullish. Loop Capital recently reiterated its Buy rating with a target of $113.</li>    <li>Disney shares had wrapped an up-and-down 2016 on a down note, finishing <font color='red'>0.8% lower</font> for the year.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3233155\" data-linked=\"Disney +2% as Evercore boosts to a top pick\" data-tweet=\"$DIS - Disney +2% as Evercore boosts to a top pick https://seekingalpha.com/news/3233155-disneyplus-2-evercore-boosts-to-top-pick?source=tweet\" data-url=\"https://seekingalpha.com/news/3233155-disneyplus-2-evercore-boosts-to-top-pick\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:48 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233154\" data-ts=\"1483461804\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BIDU\" target=\"_blank\">BIDU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233154-china-renaissance-upgrades-baidu-to-buy-on-204-target\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">China Renaissance upgrades Baidu to Buy on $204 target</a></h4><ul><li>Firm considers Q4 2016 (forecasts revenue in line and possible margin outperformance) to be a trough for Baidu and expects shares to outperform in 2017 on valuation and recovering fundamentals.</li><li>Further spotlights search rebound, CAGR within the next 3 years at a projected mid-teens level, iQiyi growth and improvements among ad tracking and margins at Baidu's O2O business.</li><li>Baidu (NASDAQ:<a href='https://seekingalpha.com/symbol/BIDU' title='Baidu, Inc.'>BIDU</a>) <font color='green'>+2.20%</font> to $168.02.</li></ul><div class=\"tiny-share-widget\" data-id=\"3233154\" data-linked=\"China Renaissance upgrades Baidu to Buy on $204 target\" data-tweet=\"$BIDU - China Renaissance upgrades Baidu to Buy on $204 target https://seekingalpha.com/news/3233154-china-renaissance-upgrades-baidu-to-buy-on-204-target?source=tweet\" data-url=\"https://seekingalpha.com/news/3233154-china-renaissance-upgrades-baidu-to-buy-on-204-target\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:43 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233153\" data-ts=\"1483461674\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PCAR\" target=\"_blank\">PCAR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233153-evercore-baird-analysts-diverge-on-paccar-outlook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Evercore, Baird analysts diverge on Paccar outlook</a></h4><ul>     <li>Paccar (<a href='https://seekingalpha.com/symbol/PCAR' title='PACCAR Inc.'>PCAR</a> <font color='green'>+1.6%</font>) is higher as two research firms <a href=\"http://thefly.com/landingPageNews.php?id=2483063&amp;headline=PCAR;ALSN;CMI;MOD;NAV;WBC;VOLVY-Battleground-Evercore-Baird-clash-on-PACCAR-outlook\" target=\"_blank\">disagree on the company's outlook</a>, with Evercore ISI upgrading PCAR to Buy from Hold and raising its price target to $77 from $59 while Baird downgrades shares to Neutral from Outperform.</li>     <li>Evercore's David Raso already had upgraded the industrials and machinery sector after the U.S. election but he has grown even more confident in the sector, predicting 2018 results would beat consensus estimates by a significant amount as the space's \"valuation is still fairly attractive,\" and PCAR in particular should benefit from strong demand for new heavy trucks in 2018.</li>     <li>However, Baird downgrades the shares on valuation concerns, noting that truck stocks outpaced the overall market by nearly 25% last year, pushing valuations near historic highs.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3233153\" data-linked=\"Evercore, Baird analysts diverge on Paccar outlook\" data-tweet=\"$PCAR - Evercore, Baird analysts diverge on Paccar outlook https://seekingalpha.com/news/3233153-evercore-baird-analysts-diverge-on-paccar-outlook?source=tweet\" data-url=\"https://seekingalpha.com/news/3233153-evercore-baird-analysts-diverge-on-paccar-outlook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:41 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233152\" data-ts=\"1483461150\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ATRX\" target=\"_blank\">ATRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233152-marina-biotech-awarded-european-patent-covering-tkrnai-technology-shares-up-13\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Marina Biotech awarded European patent covering tkRNAi technology; shares up 13%</a></h4><ul><li>Thinly traded nano cap Marina Biotech (<a href='https://seekingalpha.com/symbol/MRNA' title='Moderna, Inc.'>MRNA</a> <font color='green'>+12.7%</font>) perks up on light volume in response to its <a href=\"https://seekingalpha.com/pr/16703153-marina-biotech-granted-european-claims-covering-bacteria-mediated-gene-silencing\" target=\"_blank\">announcement </a>that the European Patent Office intends to grant it a patent for Bacteria Mediated Gene Silencing. The claims relate to its tkRNAi technology used in its <a href=\"http://www.marinabio.com/pipeline/rare-disease-programs/\" target=\"_blank\">CEQ508 </a>program for familial adenomatous polyposis.</li></ul><div class=\"tiny-share-widget\" data-id=\"3233152\" data-linked=\"Marina Biotech awarded European patent covering tkRNAi technology; shares up 13%\" data-tweet=\"$ATRX - Marina Biotech awarded European patent covering tkRNAi technology; shares up 13% https://seekingalpha.com/news/3233152-marina-biotech-awarded-european-patent-covering-tkrnai-technology-shares-up-13?source=tweet\" data-url=\"https://seekingalpha.com/news/3233152-marina-biotech-awarded-european-patent-covering-tkrnai-technology-shares-up-13\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:32 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233151\" data-ts=\"1483460906\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/F\" target=\"_blank\">F</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233151-ford-charges-ahead-ev-and-autonomous-plans\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ford charges ahead with EV and autonomous plans</a></h4><ul> <li>Ford (NYSE:<a href='https://seekingalpha.com/symbol/F' title='Ford Motor Company'>F</a>) says hybrid versions of the F-150 and Mustang will be available by 2020 in North America.</li><li>The automaker also notes that it has a memorandum of understanding with automakers in Europe to create an \"ultra-fast\" charging network\" and is running a wireless recharging pilot program in the U.S. aimed at short-distance drivers.</li> <li>Shares of Ford are <font color='green'>up 2.51%</font> to $12.44. Toyota (<a href='https://seekingalpha.com/symbol/TM' title='Toyota Motor Corporation'>TM</a> <font color='green'>+0.9%</font>) and Tesla Motors (<a href='https://seekingalpha.com/symbol/TSLA' title='Tesla, Inc.'>TSLA</a> <font color='green'>+1.5%</font>) both moved lower after the major Ford announcement, but are still in positive territory.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3233145-ford-details-ev-plans-cancels-mexico-plant-project\" target=\"_blank\">Ford details EV plans, cancels Mexico plant project</a> (Jan. 3)</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3233151\" data-linked=\"Ford charges ahead with EV and autonomous plans\" data-tweet=\"$F $F $TM - Ford charges ahead with EV and autonomous plans https://seekingalpha.com/news/3233151-ford-charges-ahead-ev-and-autonomous-plans?source=tweet\" data-url=\"https://seekingalpha.com/news/3233151-ford-charges-ahead-ev-and-autonomous-plans\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>92&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233146\" data-ts=\"1483460485\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AXSM\" target=\"_blank\">AXSM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233146-axsome-therapeutics-on-go-to-start-phase-2-3-study-of-axsminus-05-in-h1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Axsome Therapeutics on go to start Phase 2/3 study of AXS-05 in H1</a></h4><ul><li>The FDA OKs Axsome Therapeutics' (<a href='https://seekingalpha.com/symbol/AXSM' title='Axsome Therapeutics'>AXSM</a> <font color='red'>-2.2%</font>) IND for AXS-05 for the treatment of agitation in Alzheimer's patients, clearing the way for the start of a Phase 2/3 study in H1.</li><li>The <a href=\"https://seekingalpha.com/pr/16702872-axsome-therapeutics-receives-fda-clearance-ind-phase-2-3-trial-axsminus-05-alzheimer-s\" target=\"_blank\">330-subject, three-arm trial </a>will evaluate AXS-05 against placebo and bupropion, one of the components in the drug candidate. The primary endpoint will be measured by a scale called <a href=\"http://www.apa.org/pi/about/publications/caregivers/practice-settings/assessment/tools/cohen-mansfield.aspx\" target=\"_blank\">Cohen-Mansfield Agitation Inventory</a>.</li><li>AXS-05 is an orally available combination of bupropion and dextromethorphan. The role of bupropion, a norepinephrine and dopamine reuptake inhibitor and nicotinic acetylcholine receptor antagonist, is to enhance the bioavailability of dextromethorphan, an NMDA receptor antagonist, sigma-1 receptor agonist and inhibitor of the serotonin and norepinephrine transporters.</li></ul><div class=\"tiny-share-widget\" data-id=\"3233146\" data-linked=\"Axsome Therapeutics on go to start Phase 2/3 study of AXS-05 in H1\" data-tweet=\"$AXSM - Axsome Therapeutics on go to start Phase 2/3 study of AXS-05 in H1 https://seekingalpha.com/news/3233146-axsome-therapeutics-on-go-to-start-phase-2-3-study-of-axsminus-05-in-h1?source=tweet\" data-url=\"https://seekingalpha.com/news/3233146-axsome-therapeutics-on-go-to-start-phase-2-3-study-of-axsminus-05-in-h1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:21 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233150\" data-ts=\"1483460353\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LBTYA\" target=\"_blank\">LBTYA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233150-liberty-global-vodafone-wrap-dutch-joint-venture\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Liberty Global, Vodafone wrap Dutch joint venture</a></h4><ul>   <li>With the new year, Liberty Global (<a href='https://seekingalpha.com/symbol/LBTYA' title='Liberty Global, Inc.'>LBTYA</a> <font color='green'>+1.1%</font>) and Vodafone (<a href='https://seekingalpha.com/symbol/VOD' title='Vodafone Group Plc'>VOD</a> <font color='green'>+1.7%</font>) have <a href=\"https://seekingalpha.com/pr/16702584-liberty-global-vodafone-complete-dutch-joint-venture-creating-fully-converged-national\" target=\"_blank\">completed the joint venture</a> they planned to create in the Netherlands, establishing a new converged communications firm.</li>    <li>The venture -- to be called VodafoneZiggo Group -- combines Liberty's Ziggo fiber-rich broadband with Vodafone's top mobile operation into a firm with combined revenue of more than &euro;4B. The venture will sell services under both the Vodafone and Ziggo brands.</li>    <li>After closing and following recapitalization, Liberty Global will receive &euro;2.2B and Vodafone &euro;0.6B in cash.</li>    <li>Once Vodafone's divestment of its fixed business Vodafone Thuis is accounted for, net present value of synergies for the deal is estimated around &euro;3.5B. Vodafone Thuis had been generating negative cash flow (-&euro;73M in the 12 months ended September 2016).</li> </ul><div class=\"tiny-share-widget\" data-id=\"3233150\" data-linked=\"Liberty Global, Vodafone wrap Dutch joint venture\" data-tweet=\"$LBTYA $LBTYA $VOD - Liberty Global, Vodafone wrap Dutch joint venture https://seekingalpha.com/news/3233150-liberty-global-vodafone-wrap-dutch-joint-venture?source=tweet\" data-url=\"https://seekingalpha.com/news/3233150-liberty-global-vodafone-wrap-dutch-joint-venture\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233149\" data-ts=\"1483460257\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TROX\" target=\"_blank\">TROX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233149-tronox-to-rally-ebitda-to-nearly-double-in-2017-analyst-says\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tronox to rally more, EBITDA to nearly double in 2017, analyst says</a></h4><ul><li>Tronox (<a href='https://seekingalpha.com/symbol/TROX' title='Tronox Inc.'>TROX</a> <font color='green'>+4.8%</font>) shares should continue to outperform in 2017 on additional  titanium dioxide price hikes, &ldquo;positively inflecting&rdquo; ore and mineral  sands prices, Alembic Global analyst Hassan Ahmed says, Bloomberg reports.</li><li>TROX's 2017 EBITDA should nearly double to $532M, Ahmed estimates, despite modeling &ldquo;conservative assumptions&rdquo; for the  company, with a $300/ton increment in 2017 TiO2 prices along with a $160/ton hike in rutile ore prices.</li><li>TROX - which rose 164% in 2016 vs. TiO2 peers CC +312%, KRO +112% and HUN +68% - is rated Overweight with a $17 price target at Alembic.</li></ul><div class=\"tiny-share-widget\" data-id=\"3233149\" data-linked=\"Tronox to rally more, EBITDA to nearly double in 2017, analyst says\" data-tweet=\"$TROX - Tronox to rally more, EBITDA to nearly double in 2017, analyst says https://seekingalpha.com/news/3233149-tronox-to-rally-ebitda-to-nearly-double-in-2017-analyst-says?source=tweet\" data-url=\"https://seekingalpha.com/news/3233149-tronox-to-rally-ebitda-to-nearly-double-in-2017-analyst-says\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233147\" data-ts=\"1483460123\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FDC\" target=\"_blank\">FDC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233147-first-data-total-systems-rally-stephens-upgrades\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">First Data, Total Systems rally as Stephens upgrades</a></h4><ul><li>Analyst Brett Huff says investors may start rotating back into the payment processing names thanks to the big bank rally.</li><li>First Data (<a href='https://seekingalpha.com/symbol/FDC' title='First Data Corporation'>FDC</a> <font color='green'>+3.2%</font>) is&nbsp;<font color='green'>up 33%&nbsp;</font>over the last six months, but interestingly has given back most of its post-election gains, notes Huff. The market, says Huff, has \"yet to reward\" the company for improvement in North American Global Business Solutions. He upgrades to Overweight from Equalweight. The $19 price target suggests&nbsp;<font color='green'>nearly 35% upside</font>&nbsp;from last year's close.</li><li>The stock price of Total Systems Services (<a href='https://seekingalpha.com/symbol/TSS' title='Total System Services, Inc.'>TSS</a> <font color='green'>+4.4%</font>) has received very little \"Trump bump,\" says Huff. With muted Street expectations, the company needs just \"OK execution\" to top estimates. He upgrades to Overweight, with $64 price target suggesting more than&nbsp;<font color='green'>30% upside</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3233147\" data-linked=\"First Data, Total Systems rally as Stephens upgrades\" data-tweet=\"$FDC $FDC $TSS - First Data, Total Systems rally as Stephens upgrades https://seekingalpha.com/news/3233147-first-data-total-systems-rally-stephens-upgrades?source=tweet\" data-url=\"https://seekingalpha.com/news/3233147-first-data-total-systems-rally-stephens-upgrades\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:15 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233141\" data-ts=\"1483459454\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZYNE\" target=\"_blank\">ZYNE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233141-zynerba-launches-mid-stage-study-of-zyn002-in-fragile-x-syndrome-shares-up-3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Zynerba launches mid-stage study of ZYN002 in Fragile X syndrome; shares up 3%</a></h4><ul><li>Zynerba Pharmaceuticals (<a href='https://seekingalpha.com/symbol/ZYNE' title='Zynerba Pharmaceuticals'>ZYNE</a> <font color='green'>+3%</font>) <a href=\"https://seekingalpha.com/pr/16702853-zynerba-pharmaceuticals-announces-initiation-fab-c-exploratory-phase-2-clinical-trial-zyn002\" target=\"_blank\">initiates </a>an exploratory Phase 2 clinical trial evaluating co-lead product candidate ZYN002 cannabidiol &#40;CBD&#41; topical gel in children with <a href=\"https://fragilex.org/fragile-x/fragile-x-syndrome/\" target=\"_blank\">Fragile X syndrome</a>, a genetic disorder characterized by intellectual disability and behavioral and learning challenges.</li><li>The 16-subject study will evaluate 50 mg of CBD in ZYN002 4.2% gel once daily and may be titrated up to 125 mg twice daily during the six-week titration period. Primary outcome measures include changes in anxiety, depression and mood as measured by a scale called ADAMS.</li></ul><div class=\"tiny-share-widget\" data-id=\"3233141\" data-linked=\"Zynerba launches mid-stage study of ZYN002 in Fragile X syndrome; shares up 3%\" data-tweet=\"$ZYNE - Zynerba launches mid-stage study of ZYN002 in Fragile X syndrome; shares up 3% https://seekingalpha.com/news/3233141-zynerba-launches-mid-stage-study-of-zyn002-in-fragile-x-syndrome-shares-up-3?source=tweet\" data-url=\"https://seekingalpha.com/news/3233141-zynerba-launches-mid-stage-study-of-zyn002-in-fragile-x-syndrome-shares-up-3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:04 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233111\" data-ts=\"1483459254\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233111-healthcare-top-5-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/BIOS' title='BioScrip, Inc.'>BIOS</a> <font color='green'>+21%</font>. <a href='https://seekingalpha.com/symbol/CFRX' title='ContraFect Corp.'>CFRX</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/TCON' title='Tracon Pharmaceuticals'>TCON</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/TTNP' title='Titan Pharmaceuticals, Inc.'>TTNP</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/HLTH' title='Nobilis Health Corp.'>HLTH</a> <font color='green'>+10%</font>.</li><li><b>Losers:</b> ITEK <font color='red'>-70%</font>. <a href='https://seekingalpha.com/symbol/AGRX' title='Agile Therapeutics, Inc.'>AGRX</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/VYGR' title='Voyager Therapeutics'>VYGR</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/IMGN' title='ImmunoGen, Inc.'>IMGN</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/NTEC' title='Intec Pharma'>NTEC</a> <font color='red'>-9%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3233111\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am\" data-tweet=\"$BIOS $CFRX $TCON - Healthcare - Top 5 Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3233111-healthcare-top-5-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3233111-healthcare-top-5-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:00 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233131\" data-ts=\"1483458332\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IDXG\" target=\"_blank\">IDXG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233131-interpace-diagnostics-to-work-bcbs-program-to-secure-preserve-test-coverage-shares-jump-89\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Interpace Diagnostics to work with BCBS program to secure/preserve test coverage; shares jump 89%</a></h4><ul><li>Nano cap Interpace Diagnostics (<a href='https://seekingalpha.com/symbol/IDXG' title='Interpace Diagnostics Group, Inc.'>IDXG</a> <font color='green'>+88.9%</font>) rockets on an 8x surge in volume in response to its announcement that it has entered into an <a href=\"https://seekingalpha.com/pr/16702966-interpace-diagnostics-announces-agreement-blue-cross-blue-shield-bcbs-center-clinical\" target=\"_blank\">agreement</a> with the Blue Cross Blue Shield &#40;BCBS&#41; Association's Center for Clinical Effectiveness to develop the best ways to secure and preserve coverage for its tests.</li><li>The Center, called Evidence Street, gives the company an opportunity to provide evidence supporting the clinical benefits of its molecular Thyroid and Pancreas tests that will support further coverage determinations among BCBS and other health plans. Interpace will also have the opportunity to present benefit data on tests that are due to be launched in the near future.</li></ul><div class=\"tiny-share-widget\" data-id=\"3233131\" data-linked=\"Interpace Diagnostics to work with BCBS program to secure/preserve test coverage; shares jump 89%\" data-tweet=\"$IDXG - Interpace Diagnostics to work with BCBS program to secure/preserve test coverage; shares jump 89% https://seekingalpha.com/news/3233131-interpace-diagnostics-to-work-bcbs-program-to-secure-preserve-test-coverage-shares-jump-89?source=tweet\" data-url=\"https://seekingalpha.com/news/3233131-interpace-diagnostics-to-work-bcbs-program-to-secure-preserve-test-coverage-shares-jump-89\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:45 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233134\" data-ts=\"1483457854\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233134-global-yields-move-sharply-higher-out-of-2017-gate\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Global yields move sharply higher out of the 2017 gate</a></h4><ul><li>The 10-year U.S. Treasury yield is up a mere three basis points to 2.505%, but double-digit yield advances are taking place all across Western Europe, including Germany, where the 10-year Bund yield is higher by 10.2 bps to 0.286%.</li><li>Released just over 30 minutes ago, <a href=\"https://seekingalpha.com/news/3233121-ism-manufacturing-estimates-december\" target=\"_blank\">the U.S. ISM manufacturing report</a> didn't disappoint the economy bulls. The headline gauge of 54.7 rose from November and topped estimates. Both the New Orders and Production sub-indexes jumped above 60, as did Prices Paid.</li><li><a href='https://seekingalpha.com/symbol/TLT' title='iShares 20+ Year Treasury Bond ETF'>TLT</a>&nbsp;<font color='red'>-0.45%</font>, <a href='https://seekingalpha.com/symbol/TBT' title='ProShares UltraShort 20+ Year Treasury ETF'>TBT</a>&nbsp;<font color='green'>+0.9%</font></li><li>ETFs: <a href='https://seekingalpha.com/symbol/TBT' title='ProShares UltraShort 20+ Year Treasury ETF'>TBT</a>, <a href='https://seekingalpha.com/symbol/TLT' title='iShares 20+ Year Treasury Bond ETF'>TLT</a>, <a href='https://seekingalpha.com/symbol/TMV' title='Direxion Daily 20+ Year Treasury Bear 3x Shares ETF'>TMV</a>, <a href='https://seekingalpha.com/symbol/TBF' title='ProShares Short 20+ Year Treasury ETF'>TBF</a>, <a href='https://seekingalpha.com/symbol/EDV' title='Vanguard Extended Duration Treasury ETF'>EDV</a>, <a href='https://seekingalpha.com/symbol/GIM' title='Templeton Global Income Fund'>GIM</a>, <a href='https://seekingalpha.com/symbol/TMF' title='Direxion Daily 30-Year Treasury Bull 3x Shares ETF'>TMF</a>, <a href='https://seekingalpha.com/symbol/BNDX' title='Vanguard Total International Bond ETF'>BNDX</a>, <a href='https://seekingalpha.com/symbol/TTT' title='ProShares UltraPro Short 20+ Year Treasury ETF'>TTT</a>, <a href='https://seekingalpha.com/symbol/ZROZ' title='PIMCO 25+ Year Zero Coupon U.S. Treasury Index ETF'>ZROZ</a>, <a href='https://seekingalpha.com/symbol/BWX' title='SPDR Barclays International Treasury Bond ETF'>BWX</a>, <a href='https://seekingalpha.com/symbol/VGLT' title='Vanguard Long-Term Government Bond Index ETF'>VGLT</a>, <a href='https://seekingalpha.com/symbol/TLH' title='iShares 10-20 Year Treasury Bond ETF'>TLH</a>, <a href='https://seekingalpha.com/symbol/UBT' title='ProShares Ultra 20+ Year Treasury ETF'>UBT</a>, <a href='https://seekingalpha.com/symbol/DLBS' title='iPath U.S. Treasury Long Bond Bear ETN'>DLBS</a>, <a href='https://seekingalpha.com/symbol/TLO' title='SPDR Barclays Long Term Treasury ETF'>TLO</a>, <a href='https://seekingalpha.com/symbol/IGOV' title='iShares S&P/Citigroup International Treasury ETF'>IGOV</a>, <a href='https://seekingalpha.com/symbol/VUSTX' title='Vanguard Long Term Treasury Fund Inv'>VUSTX</a>, <a href='https://seekingalpha.com/symbol/DLBL' title='iPath U.S. Treasury Long Bond Bull ETN'>DLBL</a>, <a href='https://seekingalpha.com/symbol/TYBS' title='Direxion Daily 20+ Year Treasury Bear 1x Shares ETF'>TYBS</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3233134\" data-linked=\"Global yields move sharply higher out of the 2017 gate\" data-tweet=\"$TLT $TBT $TMV - Global yields move sharply higher out of the 2017 gate https://seekingalpha.com/news/3233134-global-yields-move-sharply-higher-out-of-2017-gate?source=tweet\" data-url=\"https://seekingalpha.com/news/3233134-global-yields-move-sharply-higher-out-of-2017-gate\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:37 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233128\" data-ts=\"1483456943\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LONE\" target=\"_blank\">LONE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233128-lonestar-resources-cuts-long-term-debt-third-since-june\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lonestar Resources cuts long-term debt by a third since June</a></h4><ul>     <li>Lonestar Resources (<a href='https://seekingalpha.com/symbol/LONE' title='Lonestar Resources US Inc.'>LONE</a> <font color='red'>-3%</font>) touts \"<a href=\"https://seekingalpha.com/pr/16703276-lonestar-resources-us-inc-announces-significant-reduction-long-term-debt\" target=\"_blank\">significant reductions</a>\" of its long-term debt, which now stands at $212M, down a third from $319M at the end of June.</li>     <li>LONE says at the end of 2016 it applied a portion of the proceeds of its recent $79M equity offering to repurchase $21M of its 12% second lien senior notes at 101% of par, while also repaying $49M of its revolving credit facility.</li>     <li>LONE says its stronger balance sheet will help it accelerate the development of its inventory of extended reach laterals in the Eagle Ford Shale to deliver strong production growth and position it for additional asset opportunities.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3233128\" data-linked=\"Lonestar Resources cuts long-term debt by a third since June\" data-tweet=\"$LONE - Lonestar Resources cuts long-term debt by a third since June https://seekingalpha.com/news/3233128-lonestar-resources-cuts-long-term-debt-third-since-june?source=tweet\" data-url=\"https://seekingalpha.com/news/3233128-lonestar-resources-cuts-long-term-debt-third-since-june\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:22 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233126\" data-ts=\"1483456500\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DISH\" target=\"_blank\">DISH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233126-dish-network-up-launches-music-voice-upgrades-and-new-streaming-box\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dish Network up as it launches music/voice upgrades, and new streaming box</a></h4><ul>   <li>With a number of hardware/software announcements today, Dish Network (<a href='https://seekingalpha.com/symbol/DISH' title='DISH Network Corporation'>DISH</a> <font color='green'>+3.3%</font>) looks to upgrade the home entertainment experience by making its boxes more powerful and responsive.</li>    <li>The company's the first to directly integrate voice control via Amazon's (Alexa-based) <a href=\"https://seekingalpha.com/pr/16703260-dish-amazon-deliver-alexa-voice-control-hopper-dvr\" target=\"_blank\">Echo and Dot devices</a> into its fast-developing Hopper set-top box. That will provide for customers to request programs through their Alexa device by giving commands such as \"Play the Warriors game\" or \"Watch <i>Game of Thrones</i> season 1, episode 2.\"</li>    <li>The launch of a <a href=\"https://seekingalpha.com/pr/16703259-dish-adds-multi-room-music-hopper-dvr-upcoming-launch-new-mobile-app\" target=\"_blank\">Dish Music app</a> will add multi-room music capability to its Hopper 2, Hopper 3 and connected Joey client boxes. The app uses DTS Play-Fi technology and can play popular streaming sources (including iHeartRadio, Pandora and Tidal) in various rooms through the TV-connected boxes.</li>    <li>Meanwhile, Dish has <a href=\"http://www.theverge.com/circuitbreaker/2017/1/3/14149476/dish-airtv-player-netflix-sling-tv-specs-ces-2017\" target=\"_blank\">launched the AirTV Player</a>, an Android TV streaming box that can combine over-the-air local channels with on-demand streaming and Internet TV. Sling TV, Netflix and YouTube come preinstalled (though users can add many more apps), and while channel sources remain separate, they appear integrated into the same channel guide, reducing hunting for programming.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3233126\" data-linked=\"Dish Network up as it launches music/voice upgrades, and new streaming box\" data-tweet=\"$DISH - Dish Network up as it launches music/voice upgrades, and new streaming box https://seekingalpha.com/news/3233126-dish-network-up-launches-music-voice-upgrades-and-new-streaming-box?source=tweet\" data-url=\"https://seekingalpha.com/news/3233126-dish-network-up-launches-music-voice-upgrades-and-new-streaming-box\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:15 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233122\" data-ts=\"1483456037\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CTRE\" target=\"_blank\">CTRE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233122-rbc-downgrades-quintet-of-reits\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">RBC downgrades quintet of REITs</a></h4><ul><li>We could say \"throws in the towel\" on a quintet of underperforming REITs, but not all in the group are struggling.</li><li>Downgraded to Sector Perform from Outperform are CareTrust REIT (<a href='https://seekingalpha.com/symbol/CTRE' title='CareTrust REIT'>CTRE</a> <font color='red'>-1%</font>), Extra Space Storage (<a href='https://seekingalpha.com/symbol/EXR' title='Extra Space Storage, Inc.'>EXR</a> <font color='red'>-0.7%</font>), Kilroy Realty (<a href='https://seekingalpha.com/symbol/KRC' title='Kilroy Realty Corporation'>KRC</a> <font color='red'>-0.7%</font>), and Seritage Growth (<a href='https://seekingalpha.com/symbol/SRG' title='Seritage Growth Properties'>SRG</a> <font color='red'>-1.4%</font>). Cut to Outperform from Top Pick is Regency Centers (<a href='https://seekingalpha.com/symbol/REG' title='Regency Centers Corporation'>REG</a> <font color='red'>-0.6%</font>).</li><li>Now-former Top Pick Regency Centers is about flat Y/Y, but&nbsp;<font color='red'>lower by 18%</font>&nbsp;over the last six months. Seritage and Extra Space are&nbsp;<font color='red'>down 15%</font>&nbsp;over that same time frame. CareTrust and Kilroy, however, are&nbsp;<font color='green'>ahead nearly double digits&nbsp;</font>during that period.</li></ul><div class=\"tiny-share-widget\" data-id=\"3233122\" data-linked=\"RBC downgrades quintet of REITs\" data-tweet=\"$CTRE $CTRE $EXR - RBC downgrades quintet of REITs https://seekingalpha.com/news/3233122-rbc-downgrades-quintet-of-reits?source=tweet\" data-url=\"https://seekingalpha.com/news/3233122-rbc-downgrades-quintet-of-reits\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:07 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233117\" data-ts=\"1483455621\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WATT\" target=\"_blank\">WATT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233117-energous-records-5m-investment-from-jt-group\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energous records $5M investment from JT Group</a></h4><ul><li>A tier-1 telecommunications carrier, <a href=\"http://www.jtglobal.com/Global/\" target=\"_blank\">JT Group</a>&nbsp;consequently becomes the <a href=\"https://seekingalpha.com/pr/16703240-jt-group-invests-energous-becomes-preferred-technology-solutions-partner-iot-connectivity\" target=\"_blank\">preferred connectivity partner</a> for IoT clients utilizing Energous' WattUp technology.</li><li>The company is set to showcase WattUp at CES 2017.</li><li>Energous (NASDAQ:<a href='https://seekingalpha.com/symbol/WATT' title='Energous Corp.'>WATT</a>)&nbsp;<font color='green'>+9.8%</font>&nbsp;early.</li></ul><div class=\"tiny-share-widget\" data-id=\"3233117\" data-linked=\"Energous records $5M investment from JT Group\" data-tweet=\"$WATT - Energous records $5M investment from JT Group https://seekingalpha.com/news/3233117-energous-records-5m-investment-from-jt-group?source=tweet\" data-url=\"https://seekingalpha.com/news/3233117-energous-records-5m-investment-from-jt-group\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>42&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233115\" data-ts=\"1483455558\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GFASY\" target=\"_blank\">GFASY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233115-gafisa-on-move\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gafisa on the move</a></h4><ul><li>Gafisa (GFA) starts the year on the right foot, <font color='green'>up 10%</font> in early trade.</li><li>The stock <font color='green'>gained almost 10%</font> in 2015.</li></ul><div class=\"tiny-share-widget\" data-id=\"3233115\" data-linked=\"Gafisa on the move\" data-tweet=\"$GFASY - Gafisa on the move https://seekingalpha.com/news/3233115-gafisa-on-move?source=tweet\" data-url=\"https://seekingalpha.com/news/3233115-gafisa-on-move\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:59 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233114\" data-ts=\"1483455412\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BOOT\" target=\"_blank\">BOOT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233114-analyst-upgrades-send-boot-barn-higher\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Analyst upgrades send Boot Barn higher</a></h4><ul> <li>Boot Barn (<a href='https://seekingalpha.com/symbol/BOOT' title='Boot Barn Holdings'>BOOT</a> <font color='green'>+6.1%</font>) rallies after B. Riley upgrades the retailer to a Buy rating from Neutral and JPMorgan lifts its price target to $15.50.</li> <li>Shares of Boot Barn are back over $13 for the first time in over two weeks.</li> <li>Wall Street ratings <a href=\"https://www.marketbeat.com/stocks/NYSE/BOOT/\" target=\"_blank\">scorecard</a> on Boot Barn: 5 Buys, 3 Holds, No Sells.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3233114\" data-linked=\"Analyst upgrades send Boot Barn higher\" data-tweet=\"$BOOT - Analyst upgrades send Boot Barn higher https://seekingalpha.com/news/3233114-analyst-upgrades-send-boot-barn-higher?source=tweet\" data-url=\"https://seekingalpha.com/news/3233114-analyst-upgrades-send-boot-barn-higher\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:56 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233110\" data-ts=\"1483455004\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FDML\" target=\"_blank\">FDML</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233110-icahn-bumps-bid-for-federal-mogul-to-10-share\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Icahn bumps bid for Federal-Mogul to $10/share</a></h4><ul> <li>Federal-Mogul Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/FDML' title='Federal-Mogul Corporation'>FDML</a>) is lower after Icahn Enterprises LP (<a href='https://seekingalpha.com/symbol/IEP' title='Icahn Enterprises L.P.'>IEP</a> <font color='green'>+0.5%</font>) raises its bid for the company to $10.00 per share from $9.25.</li> <li>The new offer extends the tender period to January 17.</li> <li><a href=\"https://www.sec.gov/Archives/edgar/data/921669/000119312517000392/d284508dsctota.htm\" target=\"_blank\">SEC filing</a></li> <li>FDML <font color='red'>-1.84%</font> premarket to $10.12.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3233110\" data-linked=\"Icahn bumps bid for Federal-Mogul to $10/share\" data-tweet=\"$FDML $FDML $IEP - Icahn bumps bid for Federal-Mogul to $10/share https://seekingalpha.com/news/3233110-icahn-bumps-bid-for-federal-mogul-to-10-share?source=tweet\" data-url=\"https://seekingalpha.com/news/3233110-icahn-bumps-bid-for-federal-mogul-to-10-share\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:50 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233104\" data-ts=\"1483455001\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TCON\" target=\"_blank\">TCON</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233104-tracon-pharma-clarifies-development-path-for-lead-product-candidate-shares-ahead-11\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TRACON Pharma clarifies development path for lead product candidate; shares ahead 11%</a></h4><ul><li>Thinly traded nano cap TRACON Pharmaceuticals (<a href='https://seekingalpha.com/symbol/TCON' title='Tracon Pharmaceuticals'>TCON</a> <font color='green'>+11.2%</font>) jumps out of the blocks this morning on the <a href=\"https://seekingalpha.com/pr/16702988-tracon-pharmaceuticals-receives-special-protocol-assessment-spa-agreement-fda-phase-3\" target=\"_blank\">news </a>that it has reached agreement with the FDA on the protocol design, clinical endpoints and statistical analysis method for its Phase 3 study assessing lead product candidate TRC105 for the treatment of advanced <a href=\"http://sarcomahelp.org/angiosarcoma.html\" target=\"_blank\">angiosarcoma</a>, a cancer of the inner lining of blood vessels. Enrollment should start shortly.</li><li>The 124-subject trial, called <a href=\"https://clinicaltrials.gov/ct2/show/NCT02979899?term=trc105&amp;rank=13\" target=\"_blank\">TAPPAS</a>, will evaluate the safety and efficacy of TRC105 and pazopanib [Novartis' (<a href='https://seekingalpha.com/symbol/NVS' title='Novartis AG'>NVS</a> <font color='green'>+0.2%</font>) <a href=\"http://www.hcp.novartis.com/products/votrient/?site=PS0012369&amp;source=01030&amp;IRMASRC=None\" target=\"_blank\">Votrient</a>] compared to pazopanib alone. The primary endpoint is progression-free survival. Secondary endpoints include overall survival and objective response rate.</li><li>According to ClinicalTrials.gov, the estimated final data collection date for the primary endpoint is September 2018. The estimated study completion date is December 2018.</li><li><a href=\"http://www.traconpharma.com/clinical_trials.php\" target=\"_blank\">TRC105</a>&nbsp;(carotuximab) is a novel clinical-stage antibody to endoglin, a protein overexpressed on proliferating endothelial cells that is essential for angiogenesis. It has Orphan Drug status for the treatment of soft tissue sarcoma and Fast Track status for kidney cancer.</li></ul><div class=\"tiny-share-widget\" data-id=\"3233104\" data-linked=\"TRACON Pharma clarifies development path for lead product candidate; shares ahead 11%\" data-tweet=\"$TCON $TCON $NVS - TRACON Pharma clarifies development path for lead product candidate; shares ahead 11% https://seekingalpha.com/news/3233104-tracon-pharma-clarifies-development-path-for-lead-product-candidate-shares-ahead-11?source=tweet\" data-url=\"https://seekingalpha.com/news/3233104-tracon-pharma-clarifies-development-path-for-lead-product-candidate-shares-ahead-11\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:50 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233107\" data-ts=\"1483454676\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FNJN\" target=\"_blank\">FNJN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233107-finjan-holdings-secures-license-agreement-f5-networks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Finjan Holdings secures license agreement with F5 Networks</a></h4><ul><li>Company subsidiary Finjan, Inc. <a href=\"https://seekingalpha.com/pr/16703095-finjan-signs-licensing-agreement-f5-networks\" target=\"_blank\">closes a confidential patent license agreement</a> under its enhanced licensing program set in place \"to streamline efforts, reduce costs and improve efficiencies.\"</li><li>Additionally remarks on record $18M revenue through 2016 (4x greater than 2015), attributed to enforcement efforts, and sees ongoing momentum into 2017 as multiple large litigation cases conclude and the company develops further into mobile security.</li><li>Finjan Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/FNJN' title='Finjan Holdings, Inc.'>FNJN</a>)&nbsp;<font color='green'>+13%&nbsp;</font>early.</li></ul><div class=\"tiny-share-widget\" data-id=\"3233107\" data-linked=\"Finjan Holdings secures license agreement with F5 Networks\" data-tweet=\"$FNJN - Finjan Holdings secures license agreement with F5 Networks https://seekingalpha.com/news/3233107-finjan-holdings-secures-license-agreement-f5-networks?source=tweet\" data-url=\"https://seekingalpha.com/news/3233107-finjan-holdings-secures-license-agreement-f5-networks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:44 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233096\" data-ts=\"1483453649\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VNRX\" target=\"_blank\">VNRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233096-volitionrxs-crc-screening-test-ce-markd-shares-up-13-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">VolitionRx&#39;s CRC screening test CE Mark&#39;d; shares up 13% premarket</a></h4><ul><li>VolitionRx Limited (NYSEMKT:<a href='https://seekingalpha.com/symbol/VNRX' title='VolitionRX Ltd'>VNRX</a>) is ahead&nbsp;<font color='green'>13%</font>&nbsp;premarket on light volume in response to its <a href=\"http://www.prnewswire.com/news-releases/volitionrx-limiteds-novel-cancer-diagnostic-test-achieves-ce-marking-as-it-prepares-for-launch-across-europe-300384375.html\" target=\"_blank\">announcement </a>that its <a href=\"http://volitionrx.com/nu-q\" target=\"_blank\">Nu.Q Colorectal Cancer Screening Triage Test</a> was CE Mark'd on December 28. The company says that the blood test, developed in Belgium, detects 97% of colorectal cancer &#40;CRC&#41; when combined with the fecal immunochemical test &#40;FIT&#41; score. It adds that Nu.Q has the potential to reduce colonoscopies by up to 25%.</li><li>Related ticker: (NASDAQ:<a href='https://seekingalpha.com/symbol/EXAS' title='EXACT Sciences Corporation'>EXAS</a>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3233096\" data-linked=\"VolitionRx&#39;s CRC screening test CE Mark&#39;d; shares up 13% premarket\" data-tweet=\"$VNRX $VNRX $EXAS - VolitionRx&#39;s CRC screening test CE Mark&#39;d; shares up 13% premarket https://seekingalpha.com/news/3233096-volitionrxs-crc-screening-test-ce-markd-shares-up-13-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3233096-volitionrxs-crc-screening-test-ce-markd-shares-up-13-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233092\" data-ts=\"1483453168\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DRYS\" target=\"_blank\">DRYS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233092-dryships-updates-revolving-credit-facility\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">DryShips updates revolving credit facility</a></h4><ul> <li>DryShips (NASDAQ:<a href='https://seekingalpha.com/symbol/DRYS' title='DryShips Inc.'>DRYS</a>) &nbsp;announces &nbsp;that it has signed a refinancing agreement with Sifnos Shareholders Inc.</li><li>Stifnos is an entity controlled by DryShips Chairman George&nbsp;Economou.</li> <li>Under the terms of the update revolver, Sifnos has extended a new loan of up to $200M that is secured by all of the company's present and future assets except the MV Raraka.</li><li>The new revolver carries an interest rate of Libor plus 5.5%.</li><li>\"We are pleased to have now completed the restoration of our balance sheet. With total available liquidity of $155.8 million we are now ready to begin looking at acquisition opportunities in all of the shipping sectors including drybulk vessels, tankers, and gas carriers, as the opportunities arise,\" says Economou.</li>   <li>DRYS  <font color='green'>+1.63%</font> premarket to  $3.75.</li><li>Source: <a href=\"https://seekingalpha.com/pr/16703214-dryships-announces-closing-200_0-million-new-sifnos-revolving-facility\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3233092\" data-linked=\"DryShips updates revolving credit facility\" data-tweet=\"$DRYS - DryShips updates revolving credit facility https://seekingalpha.com/news/3233092-dryships-updates-revolving-credit-facility?source=tweet\" data-url=\"https://seekingalpha.com/news/3233092-dryships-updates-revolving-credit-facility\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>51&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233090\" data-ts=\"1483453144\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233090-premarket-gainers-losers-of-9-10\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers / Losers as of 9:10 am</a></h4><ul> <li><b>Gainers:</b> LEI <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/FNBC' title='First NBC Bank Holding Company'>OTC:FNBC</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/IDXG' title='Interpace Diagnostics Group, Inc.'>IDXG</a> <font color='green'>+13%</font>. DEPO <font color='green'>+10%</font>. SGY <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/GGB' title='Gerdau S.A.'>GGB</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/FNJN' title='Finjan Holdings, Inc.'>FNJN</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/SDRL' title='Seadrill Limited &#40;New&#41;'>SDRL</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/ONVO' title='Organovo Holdings, Inc.'>ONVO</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/BLDP' title='Ballard Power Systems, Inc.'>BLDP</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/KOPN' title='Kopin Corporation'>KOPN</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/ORIG' title='Ocean Rig UDW Inc.'>ORIG</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/FCAU' title='Fiat Chrysler Automobiles NV'>FCAU</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/MTL' title='Mechel OAO'>MTL</a> <font color='green'>+5%</font>. <a href='https://seekingalpha.com/symbol/MPC' title='Marathon Petroleum Corp.'>MPC</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/CS' title='Credit Suisse Group AG'>CS</a> <font color='green'>+5%</font>. PBR-A <font color='green'>+5%</font>. <a href='https://seekingalpha.com/symbol/CEMP' title='Cempra, Inc.'>CEMP</a> <font color='green'>+5%</font>. <a href='https://seekingalpha.com/symbol/AXAS' title='Abraxas Petroleum Corporation'>AXAS</a> <font color='green'>+5%</font>.</li> <li><b>Losers:</b> ITEK <font color='red'>-64%</font>. <a href='https://seekingalpha.com/symbol/XRX' title='Xerox Corporation'>XRX</a> <font color='red'>-27%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3233090\" data-linked=\"Premarket Gainers / Losers as of 9:10 am\" data-tweet=\"$CEI $FNBC $IDXG - Premarket Gainers / Losers as of 9:10 am https://seekingalpha.com/news/3233090-premarket-gainers-losers-of-9-10?source=tweet\" data-url=\"https://seekingalpha.com/news/3233090-premarket-gainers-losers-of-9-10\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:19 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233087\" data-ts=\"1483452792\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MYOK\" target=\"_blank\">MYOK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233087-sanofi-re-ups-myokardia-in-cardiomyopathy-45m-milestone-triggered\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sanofi re-ups with MyoKardia in cardiomyopathy; $45M milestone triggered</a></h4><ul><li>MyoKardia (NASDAQ:<a href='https://seekingalpha.com/symbol/MYOK' title='MyoKardia'>MYOK</a>) is <a href=\"https://seekingalpha.com/pr/16703102-myokardia-announces-advancement-next-phase-global-collaboration-sanofi\" target=\"_blank\">eligible to receive</a> a $45M milestone payment by January 31 from cardiomyopathy collaboration partner Sanofi (NASDAQ:<a href='https://seekingalpha.com/symbol/SNY' title='Sanofi'>SNY</a>) triggered by the latter's election to continue the partnership that was formed in August 2014. Sanofi had the option of concluding the collaboration at the end of 2016 or extending the agreement.</li><li>The collaboration includes three MyoKardia programs, two in hypertrophic cardiomyopathy &#40;HCM&#41;&nbsp;and one in dilated cardiomyopathy &#40;DCM&#41;. Phase 2-stage MYK-461 is being developed to treat symptomatic obstructive HCM, an Orphan Drug designation by the FDA. DMC candidate MYK-491 should enter Phase 1 development in H1.</li><li>MyoKardia retains U.S. commercial rights to MYK-461 and discovery-phase HCM-2 and co-promotion rights to MYK-491.</li></ul><div class=\"tiny-share-widget\" data-id=\"3233087\" data-linked=\"Sanofi re-ups with MyoKardia in cardiomyopathy; $45M milestone triggered\" data-tweet=\"$MYOK $MYOK $SNY - Sanofi re-ups with MyoKardia in cardiomyopathy; $45M milestone triggered https://seekingalpha.com/news/3233087-sanofi-re-ups-myokardia-in-cardiomyopathy-45m-milestone-triggered?source=tweet\" data-url=\"https://seekingalpha.com/news/3233087-sanofi-re-ups-myokardia-in-cardiomyopathy-45m-milestone-triggered\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:13 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233080\" data-ts=\"1483451986\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FRO\" target=\"_blank\">FRO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233080-frontline-front-and-center-of-m-speculation-again\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Frontline front and center of M&amp;A speculation again</a></h4><ul> <li>Shares of Frontline (NYSE:<a href='https://seekingalpha.com/symbol/FRO' title='Frontline Ltd.'>FRO</a>) are higher in premarket trading on strong volume (+58K shares).</li> <li>Over the holiday weekend, Seeking Alpha contributor James Catlin <a href=\"https://seekingalpha.com/article/4033598-mounting-speculation-crude-tanker-consolidation\" target=\"_blank\">stoked</a> the rumors that Frontline could make a run at Gener8 Maritime (NYSE:<a href='https://seekingalpha.com/symbol/GNRT' title='Gener8 Maritime'>GNRT</a>).</li> <li>FRO <font color='green'>+4.08%</font> premarket to $7.40.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3233080\" data-linked=\"Frontline front and center of M&amp;A speculation again\" data-tweet=\"$FRO $FRO $GNRT - Frontline front and center of M&amp;A speculation again https://seekingalpha.com/news/3233080-frontline-front-and-center-of-m-speculation-again?source=tweet\" data-url=\"https://seekingalpha.com/news/3233080-frontline-front-and-center-of-m-speculation-again\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:59 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>44&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233074\" data-ts=\"1483450787\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AGN\" target=\"_blank\">AGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233074-fda-oks-allergans-inspira-breast-implants-shares-ahead-2-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA OKs Allergan&#39;s Inspira breast implants; shares ahead 2% premarket</a></h4><ul><li>The FDA <a href=\"http://www.prnewswire.com/news-releases/allergan-announces-fda-approval-of-natrelle-inspira-softtouch-breast-implants-300384060.html\" target=\"_blank\">approves </a>Allergan's (NYSE:<a href='https://seekingalpha.com/symbol/AGN' title='Allergan plc'>AGN</a>)&nbsp;NATRELLA INSPIRA SoftTouch breast implants for women undergoing breast reconstruction, augmentation or revision surgery. INSPIRA offers women a new medium firmness implant option. The NATRELLE line now offers three levels of cohesive gel alternatives.</li><li>Shares are up&nbsp;<font color='green'>2%</font>&nbsp;premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3233074\" data-linked=\"FDA OKs Allergan&#39;s Inspira breast implants; shares ahead 2% premarket\" data-tweet=\"$AGN - FDA OKs Allergan&#39;s Inspira breast implants; shares ahead 2% premarket https://seekingalpha.com/news/3233074-fda-oks-allergans-inspira-breast-implants-shares-ahead-2-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3233074-fda-oks-allergans-inspira-breast-implants-shares-ahead-2-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:39 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233063\" data-ts=\"1483450334\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PLX\" target=\"_blank\">PLX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233063-protalix-bios-cf-candidate-shows-encouraging-results-in-mid-stage-study-shares-up-5-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Protalix Bio&#39;s CF candidate shows encouraging results in mid-stage study; shares up 5% premarket</a></h4><ul><li>Nano cap Protalix BioTherapeutics (NYSEMKT:<a href='https://seekingalpha.com/symbol/PLX' title='Protalix BioTherapeutics, Inc'>PLX</a>) is up&nbsp;<font color='green'>5%</font>&nbsp;premarket on robust volume in response to its <a href=\"https://seekingalpha.com/pr/16702916-protalix-biotherapeutics-announces-positive-interim-results-phase-ii-clinical-trial\" target=\"_blank\">announcement </a>of positive interim results in a Phase 2 clinical trial assessing AIR DNase (alidornase alfa) in patients with cystic fibrosis &#40;CF&#41;.</li><li>Initial data show that alidornase alfa improved lung function by 4.1 points from baseline as measured by percent predicted forced expiratory volume in one second (ppFEV1), a favorable result compared to a mean of 2.5 achieved by a commercially available CFTR modulator.</li><li>The Phase 2 trial is a 28-day switch-over study in CF patients previously treated with Roche's (<a href='https://seekingalpha.com/symbol/RHHBY' title='Roche Holding Ltd ADR'>OTCQX:RHHBY</a>) <a href=\"http://www.pulmozyme.com/\" target=\"_blank\">Pulmozyme </a>(dornase alfa). Complete results should be available by the end of the quarter.</li><li>The company says AIR DNase is designed to treat all CF patients, not just those with certain genetic mutations.</li></ul><div class=\"tiny-share-widget\" data-id=\"3233063\" data-linked=\"Protalix Bio&#39;s CF candidate shows encouraging results in mid-stage study; shares up 5% premarket\" data-tweet=\"$PLX $PLX $RHHBY - Protalix Bio&#39;s CF candidate shows encouraging results in mid-stage study; shares up 5% premarket https://seekingalpha.com/news/3233063-protalix-bios-cf-candidate-shows-encouraging-results-in-mid-stage-study-shares-up-5-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3233063-protalix-bios-cf-candidate-shows-encouraging-results-in-mid-stage-study-shares-up-5-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:32 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233068\" data-ts=\"1483450144\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KKR\" target=\"_blank\">KKR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233068-depomedplus-11-on-report-of-kkr-interest\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Depomed +11% on report of KKR interest</a></h4><ul><li>A <a href=\"http://nypost.com/2016/12/30/kkr-is-interested-in-buying-opioid-maker-depomed/\" target=\"_blank\">weekend story in the</a> <em>NYPost</em> says <a href='https://seekingalpha.com/symbol/KKR' title='KKR'>KKR</a> isn't shying away from the opioid maker. Final bids are due on Wednesday.</li><li>KKR is already the owner of Arbor Pharmaceuticals.</li><li>Mizuho has previously suggested Depomed (DEPO) could go for more than $1.5B, or $25 per share.</li><li>The stock's&nbsp;<font color='green'>higher by 11%</font>&nbsp;premarket to $20.01.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3230024-purdue-interested-depomed-shares-12-percent\" target=\"_blank\">Purdue not interested in Depomed; shares down 12%</a> (Dec. 12, 2016)</li></ul><div class=\"tiny-share-widget\" data-id=\"3233068\" data-linked=\"Depomed +11% on report of KKR interest\" data-tweet=\"$KKR $KKR $ASRT - Depomed +11% on report of KKR interest https://seekingalpha.com/news/3233068-depomedplus-11-on-report-of-kkr-interest?source=tweet\" data-url=\"https://seekingalpha.com/news/3233068-depomedplus-11-on-report-of-kkr-interest\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>92&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233061\" data-ts=\"1483449430\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CEL\" target=\"_blank\">CEL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233061-israels-electra-buys-golan-for-91m\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Israel&#39;s Electra buys Golan for $91M</a></h4><ul><li>Electra Consumer Products has agreed to <a href=\"http://www.reuters.com/article/electra-consumer-ma-golan-idUSL5N1ET18W?type=companyNews&amp;feedType=RSS&amp;feedName=companyNews\" target=\"_blank\">buy</a> Golan Telecom for 350M shekels ($91M).</li><li>It also signed a network sharing agreement with Cellcom (NYSE:<a href='https://seekingalpha.com/symbol/CEL' title='Cellcom Israel, Ltd.'>CEL</a>), which will lend it 130M shekels to help finance the purchase.</li><li>The deal puts Golan on a stable footing after Cellcom in November filed a request for the liquidation of Golan, alleging it owed 600M shekels for using its network.</li><li>Cellcom tried to buy Golan in 2015 for about $300M but was blocked by regulators.</li><li>CEL <font color='green'>+13.5%</font> premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3233061\" data-linked=\"Israel&#39;s Electra buys Golan for $91M\" data-tweet=\"$CEL - Israel&#39;s Electra buys Golan for $91M https://seekingalpha.com/news/3233061-israels-electra-buys-golan-for-91m?source=tweet\" data-url=\"https://seekingalpha.com/news/3233061-israels-electra-buys-golan-for-91m\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:17 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233055\" data-ts=\"1483448714\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RCKT\" target=\"_blank\">RCKT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233055-inoteks-lead-product-candidate-flunks-late-stage-study-shares-plummet-68-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Inotek&#39;s lead product candidate flunks late-stage study; shares plummet 68% premarket</a></h4><ul><li>Thinly traded micro cap Inotek Pharmaceuticals (ITEK) craters&nbsp;<font color='red'>68%</font>&nbsp;premarket on robust volume in response to its <a href=\"https://seekingalpha.com/pr/16702845-inotek-announces-top-line-results-matrxminus-1-first-phase-3-trial-trabodenoson-glaucoma\" target=\"_blank\">announcement</a> that lead product candidate trabodenoson failed to beat placebo in a Phase 3 study called MATrX-1 in patients with primary open-angle glaucoma or ocular hypertension.</li><li>Trabodenoson did not achieve the primary endpoint of demonstrating superiority to placebo in reducing intraocular pressure at all 12 time points. The company says part of the problem was a higher-than-expected placebo response, specifically 2-3 mmHg greater than that observed in Phase 2.</li><li>Complete results should be available later this quarter. Management will determine the next steps in the trabodenoson monotherapy program at that time.</li><li><a href=\"http://www.inotekpharma.com/clinical-development/trabodenoson\" target=\"_blank\">Trabodenoson&nbsp;</a>is a selective adenosine mimetic that augments the natural function of the eye's&nbsp;<a href=\"https://en.wikipedia.org/wiki/Trabecular_meshwork\" target=\"_blank\">trabecular meshwork</a>, the main passageway to transport aqueous humor (fluid) out of the eye.</li></ul><div class=\"tiny-share-widget\" data-id=\"3233055\" data-linked=\"Inotek&#39;s lead product candidate flunks late-stage study; shares plummet 68% premarket\" data-tweet=\"$RCKT - Inotek&#39;s lead product candidate flunks late-stage study; shares plummet 68% premarket https://seekingalpha.com/news/3233055-inoteks-lead-product-candidate-flunks-late-stage-study-shares-plummet-68-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3233055-inoteks-lead-product-candidate-flunks-late-stage-study-shares-plummet-68-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:05 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233054\" data-ts=\"1483448678\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GRPN\" target=\"_blank\">GRPN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233054-grouponplus-3-on-rbc-upgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Groupon +3% on RBC upgrade</a></h4><ul><li>The stock's&nbsp;<font color='red'>near-45% decline</font>&nbsp;over the last five months has brought it back to a reasonable valuation, says Mark Mahaney, pulling his Underperform rating.</li><li>\"Substantial fundamental challenges\" remain though, he says, upgrading to Market Perform and reiterating his $4 price target.</li><li><a href='https://seekingalpha.com/symbol/GRPN' title='Groupon, Inc.'>GRPN</a>&nbsp;<font color='green'>+3%</font>&nbsp;to $3.42 premarket.</li></ul><div class=\"tiny-share-widget\" data-id=\"3233054\" data-linked=\"Groupon +3% on RBC upgrade\" data-tweet=\"$GRPN - Groupon +3% on RBC upgrade https://seekingalpha.com/news/3233054-grouponplus-3-on-rbc-upgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3233054-grouponplus-3-on-rbc-upgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:04 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>27&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233053\" data-ts=\"1483448662\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ANF\" target=\"_blank\">ANF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233053-two-downgrades-on-abercrombie-fitch\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Two downgrades on Abercrombie &amp; Fitch</a></h4><ul> <li>Abercrombie &amp; Fitch (NYSE:<a href='https://seekingalpha.com/symbol/ANF' title='Abercrombie & Fitch'>ANF</a>) could start the year off on a down note after two investment firms slap downgrades on the retailer.</li> <li>Oppenheimer cuts its rating to Underperform, while Jefferies moves to a Hold rating from Buy.</li> <li>ANF <font color='red'>-0.92%</font> premarket to $11.89. Shares of A&amp;F weredown 56% in 2016.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3233053\" data-linked=\"Two downgrades on Abercrombie &amp; Fitch\" data-tweet=\"$ANF - Two downgrades on Abercrombie &amp; Fitch https://seekingalpha.com/news/3233053-two-downgrades-on-abercrombie-fitch?source=tweet\" data-url=\"https://seekingalpha.com/news/3233053-two-downgrades-on-abercrombie-fitch\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:04 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233046\" data-ts=\"1483447986\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALJ\" target=\"_blank\">ALJ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233046-delek-us-buys-remaining-alon-shares-in-all-stock-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Delek US buys remaining Alon shares in all-stock deal</a></h4><ul><li>Alon USA Energy (NYSE:<a href='https://seekingalpha.com/symbol/ALJ' title='Alon USA Energy, Inc.'>ALJ</a>) <font color='green'>+10.4%</font> premarket after Delek US Holdings (NYSE:<a href='https://seekingalpha.com/symbol/DK' title='Delek US Holdings, Inc.'>DK</a>) <a href=\"https://seekingalpha.com/pr/16702908-delek-us-holdings-acquire-remaining-outstanding-shares-alon-usa\" target=\"_blank\">agrees to acquire</a> the remaining 53% of outstanding shares it  does not already own, in an all-stock deal with an equity value of $464M based on Friday's DK closing price of $12.13/share.</li><li>The enterprise value of the deal is  ~$675M, including $152M of debt; the companies say the enterprise value of the combined entity will total ~$2.8B.</li><li>DK also approves a $150M share buyback program.</li></ul><div class=\"tiny-share-widget\" data-id=\"3233046\" data-linked=\"Delek US buys remaining Alon shares in all-stock deal\" data-tweet=\"$ALJ $ALJ $DK - Delek US buys remaining Alon shares in all-stock deal https://seekingalpha.com/news/3233046-delek-us-buys-remaining-alon-shares-in-all-stock-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3233046-delek-us-buys-remaining-alon-shares-in-all-stock-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:53 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233045\" data-ts=\"1483447813\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RDHL\" target=\"_blank\">RDHL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233045-redhill-bio-to-co-promote-concordias-gi-drug-donnatal-in-u-s-shares-ahead-3-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">RedHill Bio to co-promote Concordia&#39;s GI drug Donnatal in U.S.; shares ahead 3% premarket</a></h4><ul><li>RedHill Biopharma (NASDAQ:<a href='https://seekingalpha.com/symbol/RDHL' title='RedHill Biopharma Ltd.'>RDHL</a>) is up&nbsp;<font color='green'>3%</font>&nbsp;premarket, albeit on only 810 shares, in response to its <a href=\"https://seekingalpha.com/pr/16702881-redhill-biopharma-announces-exclusive-u-s-co-promotion-agreement-concordia-gi-drug-donnatal\" target=\"_blank\">announcement </a>that it has inked a co-promotion agreement with a subsidiary of Concordia International (NASDAQ:<a href='https://seekingalpha.com/symbol/CXRX-OLD' title='Concordia International Corp'>CXRX-OLD</a>) for certain U.S. promotion rights to <a href=\"http://www.donnatal.com/\" target=\"_blank\">Donnatal </a>(phenobarbital, hyoscyamine sulfate, atropine sulfate, scopalamine hydrobromide) an oral medication used to treat irritable bowel syndrome, spastic colon and acute enterocolitis.</li><li>Under the terms of the three-year agreement, RedHill will be responsible for certain promotional activities while Concordia will supply the product. RedHill will initiate gradual promotion in the next few months.</li><li>Donnatal accounted for almost 8% of Concordia's revenues in H1 2016.</li></ul><div class=\"tiny-share-widget\" data-id=\"3233045\" data-linked=\"RedHill Bio to co-promote Concordia&#39;s GI drug Donnatal in U.S.; shares ahead 3% premarket\" data-tweet=\"$RDHL $RDHL $CXRX-OLD - RedHill Bio to co-promote Concordia&#39;s GI drug Donnatal in U.S.; shares ahead 3% premarket https://seekingalpha.com/news/3233045-redhill-bio-to-co-promote-concordias-gi-drug-donnatal-in-u-s-shares-ahead-3-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3233045-redhill-bio-to-co-promote-concordias-gi-drug-donnatal-in-u-s-shares-ahead-3-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:50 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233040\" data-ts=\"1483447123\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GM\" target=\"_blank\">GM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233040-general-motors-new-trump-twitter-target\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">General Motors a new Trump Twitter target</a></h4><ul> <li>General Motors (NYSE:<a href='https://seekingalpha.com/symbol/GM' title='General Motors Company'>GM</a>) is the target of a new <a href=\"https://twitter.com/realDonaldTrump/status/816260343391514624\" target=\"_blank\">tweet</a> from President-elect Donald Trumpo.</li><li>Trump: \"General Motors is sending Mexican made model of Chevy Cruze to U.S. car dealers-tax free across border. Make in U.S.A. or pay big border tax!\"</li>  <li>GM <font color='red'>-0.98%</font> premarket to $34.50.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3233040\" data-linked=\"General Motors a new Trump Twitter target\" data-tweet=\"$GM - General Motors a new Trump Twitter target https://seekingalpha.com/news/3233040-general-motors-new-trump-twitter-target?source=tweet\" data-url=\"https://seekingalpha.com/news/3233040-general-motors-new-trump-twitter-target\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:38 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>59&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233038\" data-ts=\"1483446883\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WYNMF\" target=\"_blank\">WYNMF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233038-macau-stocks-tripped-up-in-hong-kong-trading\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Macau stocks tripped up in Hong Kong trading</a></h4><ul> <li>Macau stocks are giving back some of their gains from last Friday after the sector generated revenue growth of 8% in December vs. 9% consensus.</li> <li>Some investors were banking on a month of double-digit growth, says Union Gaming.</li> <li>The Bloomberg Intelligence Gaming Market Index for China s down over 2%.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3232957-macau-casino-revenue-sinks-third-consecutive-year\" target=\"_blank\">Macau casino revenue sinks for third consecutive year</a> (Jan. 1)</li>   <li>Macau casino stocks: Wynn Macau (<a href='https://seekingalpha.com/symbol/WYNMF' title='Wynn Macau Ltd.'>OTCPK:WYNMF</a>, <a href='https://seekingalpha.com/symbol/WYNMY' title='Wynn Macau Ltd. ADR'>OTCPK:WYNMY</a>, <a href='https://seekingalpha.com/symbol/WYNN' title='Wynn Resorts, Limited'>WYNN</a>), Sands China (<a href='https://seekingalpha.com/symbol/SCHYY' title='Sands China Ltd ADR'>OTCPK:SCHYY</a>, <a href='https://seekingalpha.com/symbol/SCHYF' title='Sands China Ltd'>OTCPK:SCHYF</a>, <a href='https://seekingalpha.com/symbol/LVS' title='Las Vegas Sands Corp.'>LVS</a>), MGM China (<a href='https://seekingalpha.com/symbol/MCHVF' title='MGM China Holdings, Ltd.'>OTCPK:MCHVF</a>, <a href='https://seekingalpha.com/symbol/MCHVY' title='MGM China Holdings, Ltd. ADR'>OTCPK:MCHVY</a>, <a href='https://seekingalpha.com/symbol/MGM' title='MGM Resorts International'>MGM</a>), Galaxy Entertainment (<a href='https://seekingalpha.com/symbol/GXYEF' title='Galaxy Entertainment Group, Ltd.'>OTCPK:GXYEF</a>), SJM Holdings (<a href='https://seekingalpha.com/symbol/SJMHF' title='SJM Holdings Ltd.'>OTCPK:SJMHF</a>, <a href='https://seekingalpha.com/symbol/SJMHY' title='SJM Holdings Ltd. ADR'>OTCPK:SJMHY</a>), Melco Crown (MPEL).</li>     <li>Related ETF: <a href='https://seekingalpha.com/symbol/BJK' title='VanEck Vectors Gaming ETF'>BJK</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3233038\" data-linked=\"Macau stocks tripped up in Hong Kong trading\" data-tweet=\"$WYNMF $WYNMF $WYNMY - Macau stocks tripped up in Hong Kong trading https://seekingalpha.com/news/3233038-macau-stocks-tripped-up-in-hong-kong-trading?source=tweet\" data-url=\"https://seekingalpha.com/news/3233038-macau-stocks-tripped-up-in-hong-kong-trading\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:34 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233034\" data-ts=\"1483446506\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SBUX\" target=\"_blank\">SBUX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233034-starbucks-on-watch-after-nomura-call\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Starbucks on watch after Nomura call</a></h4><ul> <li>Nomura selects Starbucks (NASDAQ:<a href='https://seekingalpha.com/symbol/SBUX' title='Starbucks Corporation'>SBUX</a>) as its top restaurant pick for 2017.</li> <li>Analyst Mark Kalinowski points to the easier sales comparisions this year for the chain and thinks buy-side investors will come back on board.</li> <li>It's only a \"matter of time\" before Starbucks passes McDonald's as the largest market cap stock, according to Kalinowski.</li> <li>Source: Bloomberg</li> <li>SBUX <font color='green'>+1.03%</font> premarket to $56.09.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3233034\" data-linked=\"Starbucks on watch after Nomura call\" data-tweet=\"$SBUX - Starbucks on watch after Nomura call https://seekingalpha.com/news/3233034-starbucks-on-watch-after-nomura-call?source=tweet\" data-url=\"https://seekingalpha.com/news/3233034-starbucks-on-watch-after-nomura-call\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233032\" data-ts=\"1483446394\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HBHC\" target=\"_blank\">HBHC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233032-first-nbcplus-15-on-asset-sale\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">First NBC +15% on asset sale</a></h4><ul><li>The company <a href=\"https://seekingalpha.com/pr/16702565-first-nbc-announces-agreement-sell-nine-branches-certain-assets-liabilities-whitney-bank\" target=\"_blank\">yesterday announced the</a> sale of $1.3B in loans and and nine branches to Hancock Holding's (NASDAQ:<a href='https://seekingalpha.com/symbol/HBHC' title='Hancock Holding Company'>HBHC</a>) Whitney Bank. Alongside, Whitney will assume about $511M in deposits and $605M in FHLB borrowings.</li><li>First NBC (<a href='https://seekingalpha.com/symbol/FNBC' title='First NBC Bank Holding Company'>OTC:FNBC</a>) will pull in about $178M in cash at closing, with adjustments likely to boost total liquidity higher by more than $200M.</li><li>Along with lifting liquidity, the deal should strengthen regulatory capital ratios by 300-400 basis points.</li><li>Shares&nbsp;<font color='green'>+15.1%</font>&nbsp;premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3233032\" data-linked=\"First NBC +15% on asset sale\" data-tweet=\"$HBHC $HBHC $FNBC - First NBC +15% on asset sale https://seekingalpha.com/news/3233032-first-nbcplus-15-on-asset-sale?source=tweet\" data-url=\"https://seekingalpha.com/news/3233032-first-nbcplus-15-on-asset-sale\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:26 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233026\" data-ts=\"1483445806\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NKE\" target=\"_blank\">NKE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233026-jefferies-call-helps-to-lift-nike\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Jefferies call helps to lift Nike</a></h4><ul> <li>Shares of Nike (NYSE:<a href='https://seekingalpha.com/symbol/NKE' title='Nike Inc.'>NKE</a>) are on watch after the stock is named the best new idea for 2017 at Jefferies.</li> <li>NKE <font color='green'>+2.07%</font> premarket to $51.88 vs. a 52-week trading range of $49.01 to $65.44.</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3233026\" data-linked=\"Jefferies call helps to lift Nike\" data-tweet=\"$NKE - Jefferies call helps to lift Nike https://seekingalpha.com/news/3233026-jefferies-call-helps-to-lift-nike?source=tweet\" data-url=\"https://seekingalpha.com/news/3233026-jefferies-call-helps-to-lift-nike\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:16 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":75,"message":null,"success":true,"today":{"start":1576990800,"end":1577077199,"str":"Sunday, December 22, 2019"},"yesterday":{"start":1576904400,"end":1576990799}}